Details of the Drug

General Information of Drug (ID: DM7HXWT)

Drug Name

Nilotinib

Synonyms

NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)

Indication

Disease Entry	ICD 11	Status	REF
Chronic myelogenous leukaemia	2A20.0	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Affected Organisms

Humans and other mammals

ATC Code

L01EA03: Nilotinib

L01EA: BCR-ABL tyrosine kinase inhibitors

L01E: PROTEIN KINASE INHIBITORS

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

529.5

Logarithm of the Partition Coefficient (xlogp)

4.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is orally available []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination: 4% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 15 hours [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 21.58252 micromolar/kg/day [4]

Chemical Identifiers

Formula: C28H22F3N7O
IUPAC Name: 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
Canonical SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI: InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
InChIKey: HHZIURLSWUIHRB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 644241
ChEBI ID: CHEBI:52172
CAS Number: 641571-10-0
UNII: F41401512X
DrugBank ID: DB04868
TTD ID: D00STL
VARIDT ID: DR00013
INTEDE ID: DR1155
ACDINA ID: D00468

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Modulator	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[6]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[6]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[7]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[7]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Post-Translational Modifications	[11]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Protein Interaction/Cellular Processes	[12]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[13]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[14]
Breakpoint cluster region protein (BCR)	OTCN76C1	BCR_HUMAN	Post-Translational Modifications	[15]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Drug Response	[16]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[11]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[11]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Protein Interaction/Cellular Processes	[13]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Protein Interaction/Cellular Processes	[17]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC1; GDSC2	2.6312	4.5302	0.3378	1.2234
NOS-1 [Human HNSCC]	GDSC1; GDSC2	1.529	4.2363	-0.2012	6.1966
CHSA0011	GDSC1; GDSC2	1.8417	3.6972	1.5905	15.6474
CHSA8926	GDSC1; GDSC2	1.9142	3.8659	0.2383	2.723
HuO9	GDSC1; GDSC2	2.014	4.8336	-0.1518	4.8154
EW-13	GDSC1; GDSC2	2.1231	5.6189	-0.4538	6.3908
ES1	GDSC1; GDSC2	2.3412	4.3717	0.2571	1.9518
ES8	GDSC1; GDSC2	2.4154	4.6995	0.1541	2.3797
Hs 888.T	CTRP2	2.4646	3.2978	2.4646	23.8491
CAL-72	GDSC1; GDSC2	2.4768	4.4355	0.3009	1.562
CADO-ES1	GDSC1; GDSC2	2.7218	4.94	0.2124	1.6913
EW-24	GDSC1; GDSC2	2.7928	4.1216	0.5654	0.3053
ES7	GDSC1; GDSC2	2.8751	6.7108	-0.4853	5.1281
HuO-3N1	GDSC1; GDSC2	2.9237	6.1013	-0.182	3.4012
H-EMC-SS	GDSC1; GDSC2	2.9673	5.9671	-0.099	2.9085
EW-12	GDSC2	3.0452	4.497	2.4904	6.1291
SK-PN-DW	GDSC1; GDSC2	3.1667	5.9269	0.022	2.0667
EW-18	GDSC1; GDSC2	3.1753	5.1696	0.3305	0.7935
ES6	GDSC1; GDSC2	3.2392	5.0763	0.3922	0.5575
EW-11	GDSC1; GDSC2	3.2637	8.1679	-0.9191	6.8384
EW-3	GDSC1; GDSC2	3.2869	5.7565	0.1497	1.3856
CHSA0108	GDSC1; GDSC2	3.4355	5.2075	2.472	4.8849
ES5	GDSC1; GDSC2	3.5262	8.5546	0.8738	14.179
EW-22	GDSC1; GDSC2	3.5309	5.7424	0.2624	0.7856
SaOS-2	GDSC1; GDSC2; CTRP2; CCLE	3.6703	5.4627	3.5859	16.105
SK-ES-1	GDSC1; GDSC2; CTRP2; CCLE	3.7313	6.5068	3.3802	16.6606
ES4	GDSC1; GDSC2	3.7687	5.5822	0.4136	0.2844
NY	GDSC1; GDSC2	3.7799	8.6328	-0.8242	5.472
EW-7	GDSC1; GDSC2	3.7833	9.9135	-1.406	8.4998
EW-1	GDSC1; GDSC2	3.7847	5.6371	0.4003	0.3055
U-CH2	GDSC2	4.1537	6.5324	2.3457	4.1391
EW-16	GDSC1; GDSC2	4.5433	6.8171	0.266	0.333
A-673	GDSC1; GDSC2; CTRP2	4.8939	7.7681	4.1034	10.69
TC-71	GDSC1; GDSC2; CCLE	5.1453	6.6734	2.5022	0.2599
Hs 822.T	CTRP2	7.0347	8.0751	5.6878	0.3673
CAL-78	GDSC1; GDSC2; CTRP2; CCLE	7.3683	9.5361	5.2394	1.5261
SK-N-MC	CTRP2	7.4279	8.4725	5.7021	0.1679
MG-63	GDSC1; GDSC2; CTRP2; CCLE	7.5673	9.1323	5.5099	0.5288
HOS	GDSC1; GDSC2; CTRP2; CCLE	7.908	9.5355	5.5017	0.3833
SW1353	CTRP2; CCLE	8.4004	9.8706	5.5708	0.1299
G-292 clone A141B1	GDSC1; GDSC2; CTRP2	8.403	10.0472	5.5099	0.2088
U2OS	GDSC1; GDSC2; CTRP2; CCLE	8.5874	10.6244	5.3724	0.3853
SJSA-1	GDSC1; GDSC2; CTRP2	8.7185	10.4729	5.477	0.1836
MHH-ES-1	GDSC1; GDSC2; CTRP2; CCLE	11.7902	21.2802	2.5144	6.5155
-----------


⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 224 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	-11.0873	-0.6103	-11.3428	85.1305
MEC1	CTRP2	7.5941	8.9815	5.5802	0.3467
JM1	GDSC1; GDSC2; CTRP2	7.7989	10.2592	5.1571	1.4139
ALL-SIL	GDSC1; GDSC2; CTRP2; CCLE	-9.6949	-1.1764	-9.8264	84.8535
MOLM-6	CTRP2	-9.1904	-5.7957	-9.1905	93.587
KYO-1	CTRP2	-9.0154	-6.8631	-9.0154	95.6397
EoL-1	GDSC1; GDSC2; CTRP2	-8.9301	-5.7639	-8.9302	93.2263
Ku812	GDSC1; GDSC2; CTRP2; CCLE	-8.3987	-4.8129	-8.3992	90.413
BV-173	GDSC1; GDSC2; CTRP2	-8.3341	0.0431	-8.5057	80.7807
JURL-MK1	GDSC1; CTRP2	-8.0747	-5.7831	-8.0747	91.5998
LAMA-84	GDSC1; GDSC2; CTRP2	-7.701	-5.5888	-7.701	90.0518
EM-2	GDSC1; GDSC2; CTRP2; CCLE	-7.39	-0.8193	-7.4562	80.4796
NCO2	CTRP2; CCLE	-7.263	-5.0237	-7.263	87.4855
MEG-01	GDSC1; GDSC2; CCLE	-6.6416	-4.8454	-6.6416	80.1942
CML-T1	GDSC1; GDSC2; CTRP2	-6.134	-1.9279	-6.1406	78.5389
KCL-22	GDSC1; GDSC2; CTRP2; CCLE	-5.9498	-3.8985	-5.9498	79.6658
K-562	GDSC1; GDSC2; CTRP2	-4.3363	6.4888	-5.4088	62.0977
Kasumi-1	GDSC1; GDSC2; CTRP2	-4.0562	-1.3452	-4.0569	67.1414
BE-13	GDSC1; GDSC2	-2.476	11.3692	-7.3053	44.3392
MY-M12	GDSC1; GDSC2	-1.8331	51.5453	-25.2099	49.9939
NKM-1	GDSC1; GDSC2	0.2271	4.3057	-1.3342	17.0596
OCI-Ly7	GDSC1; GDSC2	0.2734	2.301	0.208	29.8533
CTV-1	GDSC1; GDSC2	0.8612	2.5195	0.1216	5.9786
KMS-34	CTRP2; CCLE	0.9623	2.5921	0.9607	33.8629
KMOE-2	GDSC1; GDSC2	1.2679	3.6326	-0.1002	6.2242
GA-10	GDSC1; GDSC2	1.3242	3.6882	-0.0844	5.9785
Ramos.2G6.4C10	GDSC1; GDSC2	1.3474	4.5754	-0.5071	8.5658
HAL-01	GDSC1; GDSC2	1.3492	4.3379	-0.3876	7.8141
SU-DHL-5	GDSC1; GDSC2	1.3769	3.783	-0.0912	5.8869
SUP-B8	GDSC1; GDSC2	1.3918	2.5588	1.3644	18.8338
KMM-1	CCLE	1.464	4.8679	0.6041	17.3707
Karpas-1106P	GDSC1; GDSC2	1.5086	4.4552	-0.3242	7.0114
ME1	GDSC1; GDSC2	1.5118	3.0806	0.3491	2.8489
MOLT-4	GDSC1; GDSC2	1.5321	3.347	0.2349	3.4981
CCRF-CEM	GDSC1; GDSC2	1.6192	5.1008	-0.56	8.1962
MHH-PREB-1	GDSC1; GDSC2	1.6263	3.2584	0.3404	2.6678
P32/ISH	GDSC1; GDSC2	1.6314	3.6891	0.1383	3.8701
VAL	GDSC1; GDSC2	1.6986	5.0358	-0.4694	7.445
U-698-M	GDSC1; GDSC2	1.7096	3.5806	0.2423	3.0842
KOPN-8	GDSC1; GDSC2	1.7244	3.3029	0.3817	2.2422
KMS-18	CTRP2	1.7432	3.2932	1.7401	28.6656
IM-9	GDSC1; GDSC2	1.7562	3.0596	0.5112	1.4674
RPMI-8866	GDSC1	1.7966	5.2667	-0.5114	9.251
HuT 78	CCLE	1.8212	3.6377	1.4968	11.6524
DB	GDSC1; GDSC2; CTRP2	1.8437	4.7736	1.7341	28.3556
WSU-NHL	GDSC1; GDSC2	1.8468	4.3385	-0.0272	4.4134
KMS-28BM	CTRP2	1.8855	4.6296	1.7992	27.9981
Karpas-45	GDSC1; GDSC2	1.955	3.8341	0.2776	2.4303
ML-2	GDSC1; GDSC2	1.9834	4.4322	0.0179	3.8721
SUP-B15	GDSC1; GDSC2; CTRP2	2.0126	30.175	-9.5261	43.4493
KY821	GDSC1; GDSC2	2.0188	4.6781	-0.0751	4.3506
CTB-1	GDSC1; GDSC2	2.0569	6.7854	0.4489	21.1595
Daudi	GDSC1; GDSC2; CTRP2	2.061	3.2408	2.0604	26.5398
BALL-1	GDSC1; GDSC2	2.0654	4.4493	0.0617	3.4634
WIL2 NS	GDSC1; GDSC2	2.0775	4.2423	0.1645	2.8566
OCI-AML-3	GDSC1; GDSC2; CTRP2	2.1002	6.266	1.6775	27.7261
GR-ST	GDSC1; GDSC2	2.1808	6.5264	-0.8517	8.6327
ARH-77	GDSC1; GDSC2	2.2185	4.4846	0.1379	2.7692
HD-MY-Z	CTRP2	2.2258	3.4812	2.2243	25.445
KMS-11	GDSC1; GDSC2; CTRP2; CCLE	2.2372	5.2752	2.0714	25.9299
SCC-3	GDSC2	2.2399	7.3598	-1.2151	10.6148
MN-60	GDSC1; GDSC2	2.2767	4.2676	0.2675	1.9879
MEC-1	CCLE	2.2808	5.6667	1.0284	12.6076
Karpas-231	GDSC1; GDSC2	2.2904	3.8958	0.4336	1.1574
ALL-PO	GDSC1; GDSC2	2.2989	6.4581	-0.7371	7.697
LC4-1	GDSC1; GDSC2	2.3267	8.8487	-1.8811	14.0714
YT	GDSC1; GDSC2	2.3481	7.4729	-1.1934	10.2412
Farage	GDSC1; GDSC2	2.3749	5.8856	1.1852	15.9432
Loucy	GDSC1; GDSC2	2.382	4.0573	0.4117	1.157
H9	GDSC1; GDSC2	2.3937	6.6576	-0.7686	7.6792
TK [Human B-cell lymphoma]	GDSC1; GDSC2	2.4487	4.0386	0.4512	0.9198
RC-K8	GDSC1; GDSC2	2.4569	4.314	0.3419	1.3922
PL-21	GDSC1; GDSC2	2.5116	4.857	1.8063	11.8199
QIMR-WIL	GDSC1; GDSC2	2.5345	5.0438	1.7408	12.1259
697	GDSC1; GDSC2; CTRP2; CCLE	2.54	4.3943	2.5139	23.4343
ATN-1	GDSC1; GDSC2	2.588	4.3423	0.3937	1.0276
Jiyoye	GDSC1; GDSC2	2.6319	4.5281	0.339	1.2174
THP-1	GDSC1; GDSC2; CTRP2	2.6445	3.8684	2.642	22.6588
NK-92MI	GDSC2	2.646	3.4848	2.5342	7.3848
SIG-M5	GDSC2; CTRP2; CCLE	2.6571	3.9882	2.6526	22.5814
TALL-1 [Human adult T-ALL]	GDSC2; CTRP2	2.693	5.8048	2.4494	23.1712
BC-3	GDSC2	2.7161	3.5522	2.5861	6.7872
JM-1	CCLE	2.7386	4.8398	1.8541	6.892
AML-193	CTRP2	2.7483	4.0213	2.7444	21.9722
TUR	GDSC1; GDSC2	2.7705	4.6859	0.3404	1.0785
CRO-AP2	GDSC1; GDSC2	2.8057	5.9296	1.5663	12.2602
Hs 445	GDSC2	2.821	4.8324	0.3049	1.1778
VL51	GDSC1; GDSC2	2.8389	5.0567	0.2219	1.5184
CESS	GDSC1; GDSC2	2.8794	4.5754	0.4319	0.6504
JSC-1	GDSC1; GDSC2	2.9126	5.5576	0.0486	2.2437
L-428	GDSC1; GDSC2; CTRP2; CCLE	2.9157	4.3222	2.9061	20.8759
MOLT-3	CTRP2	2.9612	6.463	2.5566	21.9679
KMS-21-BM	CTRP2	3.0333	17.324	-2.2665	34.8574
HH [Human lymphoma]	GDSC1; GDSC2; CTRP2; CCLE	3.0463	6.2439	2.7159	21.1342
BC-1	GDSC1; GDSC2	3.0514	5.062	0.3184	0.9273
SU-DHL-16	GDSC1; GDSC2	3.0775	5.2724	2.1362	7.9641
MHH-CALL-2	GDSC1; GDSC2	3.1019	4.6351	0.4994	0.3361
DoHH2	GDSC1; GDSC2; CCLE	3.1193	4.1205	2.7433	3.5798
DG-75	GDSC1; GDSC2	3.1468	5.2075	0.3035	0.9087
MLMA	GDSC1; GDSC2	3.1477	10.472	-2.0876	13.2447
Mono-Mac-1	CTRP2; CCLE	3.2967	7.5388	2.5373	21.06
SUP-M2	GDSC1; GDSC2; CCLE	3.2988	4.8432	2.314	2.9552
HC-1	GDSC1; GDSC2	3.341	4.9332	0.4836	0.2819
Sc-1	GDSC1	3.3446	4.6131	0.5949	0.1233
P30/OHK	GDSC1; GDSC2	3.384	4.8979	0.5116	0.214
OPM-2	GDSC1; GDSC2; CTRP2; CCLE	3.4302	5.8784	3.2351	18.0944
EB1	CTRP2; CCLE	3.667	5.4545	3.5838	16.1227
RS4;11	GDSC1; GDSC2; CTRP2	3.7431	10.5893	1.6534	23.0901
L-1236	GDSC1; GDSC2	3.7446	6.1173	0.2098	0.8213
KG-1	GDSC1; GDSC2; CCLE	3.7535	6.8822	1.6454	5.5106
SUP-T11	CTRP2	3.8242	5.7547	3.694	15.2411
DEL	GDSC1; GDSC2; CTRP2; CCLE	3.9006	4.8862	3.8931	14.3074
BDCM	CCLE	3.9269	5.8106	2.2714	2.1506
CA46	GDSC1; GDSC2; CTRP2	4.016	6.088	3.8187	14.205
BL-41	GDSC1; GDSC2; CCLE	4.0368	5.8844	2.3028	1.7972
Karpas-620	GDSC1; GDSC2; CTRP2; CCLE	4.1938	7.2756	3.5931	14.5417
KE-37	GDSC1; GDSC2; CTRP2	4.2175	7.6078	3.4806	14.9141
ROS-50	GDSC1; GDSC2	4.2201	7.5081	1.9219	6.3336
BONNA-12	GDSC2	4.3817	7.0153	2.2661	4.1576
U-937	CTRP2; CCLE	4.3883	7.7905	3.5791	14.0751
KMS-12-BM	GDSC1; GDSC2; CTRP2; CCLE	4.405	8.088	3.465	14.4825
MOLP-2	CTRP2	4.4086	7.5137	3.7194	13.4704
HPB-ALL	CTRP2	4.5428	8.9152	3.2236	15.0986
CMK-86	CCLE	4.5824	7.9505	1.6863	4.0086
Pfeiffer	CTRP2; CCLE	5.1282	8.6009	3.9405	10.7853
MJ	CCLE	5.1301	10.4382	0.8709	7.1191
Namalwa	GDSC1; GDSC2; CTRP2	5.4742	9.0648	4.0361	9.609
A4/Fukuda	GDSC1; GDSC2; CTRP2	5.7507	12.4809	1.8971	12.6
EB2	GDSC1; GDSC2; CCLE	5.9173	7.6966	2.4277	0.182
HEL 92.1.7	CTRP2; CCLE	5.9587	7.0191	4.6749	0.4827
SET-2	CTRP2	5.9699	8.2994	4.8542	5.1483
Hs 611.T	CTRP2	6.4251	10.5251	4.1129	7.4101
KO52	CTRP2; CCLE	6.7455	12.2927	3.4836	9.4513
REC-1	CTRP2	6.8037	13.4422	2.9577	11.4726
Toledo	CTRP2; CCLE	6.9308	9.3475	5.0603	2.7058
MC116	GDSC1; GDSC2; CTRP2; CCLE	6.9868	12.8695	3.3819	9.4531
SU-DHL-10	GDSC2; CTRP2; CCLE	6.99	8.1532	5.6348	0.5465
SU-DHL-1	GDSC2; CTRP2	7.065	8.2432	5.6342	0.4964
Ci-1	CTRP2; CCLE	7.0905	8.5246	5.5294	0.7976
KMS-26	CTRP2; CCLE	7.0961	14.8467	2.486	12.7999
LP-1	GDSC1; GDSC2; CTRP2; CCLE	7.1357	9.7745	4.9915	2.7095
A3/Kawakami	GDSC1; GDSC2; CTRP2	7.167	8.2248	5.6879	0.2973
WSU-DLCL2	GDSC1; GDSC2; CTRP2	7.2875	8.8512	5.4916	0.7619
P12-Ichikawa	GDSC1; GDSC2; CTRP2; CCLE	7.3385	13.5727	3.2967	9.2185
Karpas-299	GDSC1; GDSC2; CTRP2; CCLE	7.3729	9.2811	5.3531	1.1343
OCI-AML-2	GDSC1; GDSC2; CTRP2; CCLE	7.3739	8.4709	5.6812	0.2243
Karpas-422	GDSC1; GDSC2; CTRP2; CCLE	7.4057	8.6772	5.6164	0.3503
NOMO-1	GDSC1; GDSC2; CTRP2	7.4497	8.9546	5.527	0.5516
RL	GDSC1; GDSC2; CTRP2	7.4545	10.1724	5.0035	2.2867
HEL	GDSC1; GDSC2; CTRP2	7.4662	8.918	5.5491	0.4842
OCI-AML-5	GDSC1; CTRP2; CCLE	7.4819	8.395	5.7499	0.0857
TF-1	CTRP2	7.4823	8.6912	5.6432	0.2592
Mino	CTRP2; CCLE	7.4905	8.6077	5.6774	0.1916
MOLM-13	GDSC1; GDSC2; CTRP2	7.5003	16.4706	1.9893	13.9556
SKM-1	GDSC1; GDSC2; CTRP2	7.5185	9.184	5.4667	0.675
MOTN-1	CTRP2	7.521	10.5908	4.8521	2.7763
HuNS1	CTRP2	7.5438	11.5656	4.4111	4.4518
KMS-27	CTRP2	7.5496	14.6091	2.9425	10.2799
EJM	GDSC1; GDSC2; CTRP2	7.5556	11.0225	4.6737	3.4141
OCI-M1	GDSC1; GDSC2; CTRP2	7.5582	8.8426	5.6177	0.2818
Mono-Mac-6	GDSC1; GDSC2; CTRP2	7.5703	15.895	2.3258	12.602
Granta-519	GDSC1; GDSC2; CTRP2; CCLE	7.6191	9.4679	5.3988	0.8024
SEM	CTRP2	7.6212	8.8859	5.6271	0.2401
BL-70	CTRP2; CCLE	7.6611	8.5845	5.7486	0.0591
NU-DUL-1	GDSC1; GDSC2; CTRP2	7.6907	9.6333	5.3655	0.8504
P31/FUJ	GDSC1; GDSC2; CTRP2; CCLE	7.7306	9.1139	5.5868	0.2786
HL-60	GDSC1; GDSC2; CTRP2	7.742	9.0313	5.6216	0.2108
KE-97	CTRP2; CCLE	7.7698	9.8872	5.2992	0.9908
KMS-20	CTRP2	7.7721	16.5037	2.1755	12.8269
NB4	GDSC1; GDSC2; CTRP2	7.7769	8.7282	5.7404	0.0523
SU-DHL-4	GDSC1; GDSC2; CTRP2; CCLE	7.7785	12.8024	3.9784	5.842
OCI-Ly3	CTRP2	7.7961	9.07	5.6286	0.1838
MV4-11	GDSC1; GDSC2; CTRP2	7.8059	20.7189	0.1185	19.5156
SU-DHL-6	GDSC1; GDSC2; CTRP2; CCLE	7.8064	11.213	4.739	2.8749
CMK	GDSC1; CTRP2	7.8242	8.9702	5.6743	0.1127
NALM-6	GDSC1; GDSC2; CTRP2	7.8304	9.5975	5.4444	0.552
HT	GDSC1; GDSC2; CTRP2; CCLE	7.8397	9.1662	5.6107	0.2005
L-540	GDSC1; GDSC2; CTRP2	7.8654	9.8499	5.3601	0.7522
MM1.S	GDSC1; GDSC2; CTRP2	7.9859	9.4441	5.5668	0.231
Jurkat	GDSC1; GDSC2; CTRP2; CCLE	7.9944	9.3693	5.5969	0.1808
GDM-1	GDSC1; GDSC2; CTRP2	8.0013	10.176	5.2921	0.855
Raji	GDSC1; GDSC2; CTRP2; CCLE	8.0148	9.3416	5.6144	0.1511
MOLP-8	GDSC1; GDSC2; CTRP2; CCLE	8.0484	9.6706	5.5086	0.3155
MOLT-16	GDSC1; GDSC2; CTRP2; CCLE	8.0599	9.3774	5.6184	0.1363
ME1	CTRP2	8.0687	9.5946	5.5444	0.2443
SUP-HD1	GDSC1; GDSC2; CTRP2	8.0861	10.2431	5.3045	0.77
PL21	CTRP2	8.087	9.5556	5.5656	0.2048
KHM-1B	CTRP2; CCLE	8.0998	9.8286	5.4707	0.3711
RPMI-6666	GDSC1; GDSC2; CTRP2	8.1022	9.6828	5.5255	0.2667
OCI-Ly19	GDSC1; GDSC2; CTRP2	8.1296	9.7688	5.5048	0.2948
SUP-T1	GDSC1; GDSC2; CTRP2; CCLE	8.1306	9.7725	5.5039	0.2963
NCI-H929	GDSC1; GDSC2; CTRP2	8.1337	9.6705	5.5422	0.2293
SK-MM-2	GDSC1; GDSC2; CTRP2; CCLE	8.1505	10.1238	5.3799	0.5475
OCI-Ly10	CTRP2	8.2019	11.4963	4.8371	2.1259
MOLM-16	GDSC1; GDSC2; CTRP2	8.2315	9.7011	5.5682	0.1662
M-07e	CTRP2	8.2371	9.9695	5.4738	0.3158
Ri-1	CTRP2	8.2578	19.0146	1.2987	15.1074
U266B1	GDSC1; GDSC2; CTRP2	8.2839	9.8697	5.5281	0.2113
Reh	GDSC1; GDSC2; CTRP2; CCLE	8.2875	9.8499	5.5365	0.1979
RPMI-8402	GDSC1; GDSC2; CTRP2; CCLE	8.3064	9.6351	5.6181	0.0945
ST486	GDSC1; GDSC2; CTRP2	8.3068	9.7398	5.5823	0.1333
RPMI-8226	GDSC1; GDSC2; CTRP2	8.3235	9.7217	5.5945	0.1164
P3HR-1	CTRP2; CCLE	8.3375	16.6078	2.5301	10.6374
SR	GDSC1; GDSC2; CTRP2	8.3388	9.9825	5.5087	0.2268
SU-DHL-8	GDSC2; CTRP2; CCLE	8.3422	17.122	2.2841	11.5359
DND-41	GDSC1; GDSC2; CTRP2	8.3881	10.1541	5.4658	0.2824
MOLT-13	GDSC1; GDSC2; CTRP2	8.3911	9.8281	5.5821	0.1188
AMO1	GDSC1; GDSC2; CTRP2; CCLE	8.4156	18.4954	1.6674	13.6116
KM-H2	GDSC1; GDSC2; CTRP2	8.418	10.5268	5.3395	0.5176
JJN-3	GDSC1; GDSC2; CTRP2	8.4856	14.7454	3.5213	6.6741
Ki-JK	CTRP2	8.5347	10.1224	5.5321	0.151
F-36P	CTRP2; CCLE	8.5437	13.5997	4.0905	4.4508
PF-382	GDSC1; GDSC2; CTRP2	8.7049	10.306	5.5299	0.1244
MHH-CALL-4	GDSC2; CTRP2	8.7171	10.3465	5.5203	0.1327
EHEB	GDSC1; CTRP2	8.7272	10.2528	5.5558	0.0961
HDLM-2	GDSC1; GDSC2; CTRP2	8.7614	10.7619	5.3906	0.2993
JVM-3	GDSC1; GDSC2; CTRP2; CCLE	8.7699	16.5807	2.8379	8.8753
Kasumi-2	CTRP2; CCLE	8.8954	15.4568	3.4488	6.4285
JVM-2	GDSC1; GDSC2; CTRP2	9.039	11.2905	5.3069	0.3578
MHH-CALL-3	CTRP2	9.1724	11.1269	5.4147	0.1734
RCH-ACV	GDSC1; GDSC2; CTRP2	9.4606	20.5008	1.427	12.8768
JeKo-1	GDSC1; GDSC2; CTRP2	10.2465	19.4444	2.4384	8.426
Peer	CTRP2	10.8257	35.0019	-4.6686	25.3732
L-363	GDSC1; GDSC2; CTRP2; CCLE	12.0421	25.6153	0.6912	11.8678
-----------


⏷ Show the Full List of 224 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	7.4148	10.6433	4.762	3.248
TE8	CTRP2	8.7773	10.56	5.4682	0.183
T.T	GDSC1; GDSC2	1.574	3.8826	0.0046	4.8159
TE-8	GDSC1; GDSC2	2.9254	5.3021	0.1627	1.6913
KYSE-410	GDSC1; GDSC2; CTRP2; CCLE	3.1525	4.737	3.1268	19.3524
TE-5	GDSC1; GDSC2; CTRP2	3.2974	5.4698	3.1815	18.6982
TE-4	GDSC1; GDSC2	3.2995	5.082	0.4142	0.4647
TE-6	GDSC1; GDSC2; CTRP2	3.4345	4.7732	3.3534	11.7902
OE21	GDSC1; GDSC2; CTRP2; CCLE	3.5958	5.6385	3.471	16.7426
KYSE-270	GDSC1; GDSC2	4.2255	6.126	0.3901	0.206
TE-15	GDSC1	4.6366	6.5466	0.3908	0.1644
TE-11	GDSC1; GDSC2; CTRP2	7.6882	9.0753	4.602	0.0679
OE19	GDSC1; GDSC2; CTRP2	7.9634	9.8204	5.416	0.5533
KYSE-450	GDSC1; GDSC2; CTRP2	7.9816	10.112	5.3087	0.8215
EC-GI-10	GDSC1; GDSC2; CTRP2	8.0174	9.6256	5.5128	0.3185
KYSE-30	CTRP2; CCLE	8.1066	9.2217	5.6883	0.0576
KYSE-150	GDSC1; GDSC2; CTRP2	8.1147	9.2849	5.6698	0.072
COLO 680N	GDSC1; GDSC2; CTRP2	8.1213	9.4945	5.6	0.1474
TE-9	GDSC1; GDSC2; CTRP2; CCLE	8.3103	9.8082	5.5597	0.1607
TE-1	GDSC1; GDSC2; CTRP2	8.3468	10.0205	5.4981	0.2412
OE33	GDSC1; GDSC2; CTRP2; CCLE	8.3536	10.0282	5.4979	0.2396
TE-14	CTRP2	8.4446	9.9539	5.5579	0.1369
KYSE-70	GDSC1; GDSC2; CTRP2	8.4637	9.9536	5.5649	0.1257
KYSE-510	GDSC1; GDSC2; CTRP2	8.5738	9.9668	5.5991	0.0775
TE-10	GDSC1; GDSC2; CTRP2	8.5742	10.4698	5.4237	0.2983
KYSE-520	GDSC1; GDSC2; CTRP2; CCLE	8.6991	10.6696	5.3998	0.3018
KYSE-140	GDSC1; GDSC2; CTRP2	8.9735	16.502	3.0087	7.969
KYSE-180	GDSC1; GDSC2; CTRP2	11.3307	21.6528	2.0817	8.3838
-----------


⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	8.0796	9.432	5.6066	0.1476
PaTu 8988s	CTRP2	2.1961	3.0967	2.196	25.6381
Panc 10.05	GDSC1; GDSC2; CTRP2; CCLE	3.4654	4.7953	3.4485	17.2384
PL45	CCLE	3.6649	5.6415	2.1838	3.0162
MIA PaCa-2	GDSC1; GDSC2; CTRP2; CCLE	3.6809	5.5355	3.584	16.0781
KP-1N	GDSC1; GDSC2; CCLE	3.7819	7.285	1.469	6.3611
PL4	GDSC1; GDSC2	3.8164	5.7805	0.3615	0.3761
PK-1	CCLE	3.9249	6.132	2.1213	2.8916
KP-1NL	CCLE	4.0101	6.7099	1.9042	3.8441
SU.86.86	GDSC1; GDSC2; CTRP2	4.1264	5.4773	4.0743	12.955
Capan-1	GDSC1; GDSC2; CTRP2	4.2317	5.9919	4.0802	12.6049
MZ-PC-1	GDSC1; GDSC2	4.241	6.7643	2.2933	4.127
AsPC-1	GDSC1; GDSC2; CTRP2; CCLE	4.2815	7.9102	3.4171	14.9931
SNU-410	CTRP2	4.8102	10.9281	2.5107	17.2893
PSN1	GDSC1; GDSC2; CTRP2	4.8932	7.0322	4.4278	9.4032
KP-4	GDSC1; GDSC2; CTRP2; CCLE	5.0073	6.3864	4.8037	7.6423
KP-2	GDSC1; GDSC2; CTRP2; CCLE	6.0488	6.7529	5.6938	1.4653
PaTu 8902	GDSC1; GDSC2; CTRP2	6.964	9.5962	4.964	3.0429
DAN-G	GDSC1; GDSC2; CTRP2	7.7389	13.9197	3.4139	8.1337
PaTu 8988t	GDSC1; GDSC2; CTRP2	7.7428	8.9685	5.6446	0.1729
Panc 03.27	GDSC1; GDSC2; CTRP2; CCLE	7.7892	11.4494	4.6205	3.337
YAPC	GDSC1; GDSC2; CTRP2	7.8823	9.0875	5.6546	0.126
SW1990	GDSC1; GDSC2; CTRP2; CCLE	7.9456	13.5385	3.7388	6.5555
HPAF-II	GDSC1; GDSC2; CTRP2	7.9979	10.1734	5.2916	0.8586
HPAC	GDSC1; GDSC2; CTRP2; CCLE	8.0388	9.5752	5.5398	0.2614
Panc 05.04	CTRP2	8.0407	14.9905	3.1059	8.8916
SNU-213	CTRP2	8.0616	9.4294	5.6008	0.1593
QGP-1	GDSC1; GDSC2; CTRP2	8.0844	9.961	5.4141	0.4995
Panc 04.03	GDSC1; GDSC2; CTRP2; CCLE	8.2388	13.7868	3.8136	5.8725
BxPC-3	GDSC1; GDSC2; CTRP2	8.2461	11.1335	5.0159	1.5026
SUIT-2	GDSC1; GDSC2; CTRP2; CCLE	8.2603	9.6643	5.5916	0.1308
Panc 02.03	GDSC1; GDSC2; CTRP2; CCLE	8.2731	9.7297	5.5735	0.1505
HuP-T3	GDSC1; GDSC2; CTRP2; CCLE	8.3558	10.6036	5.2832	0.6768
Hs 766T	GDSC1; GDSC2; CTRP2; CCLE	8.3887	9.8625	5.5693	0.1336
TCC-Pan2	CTRP2	8.4331	9.7898	5.61	0.085
Panc 08.13	GDSC1; GDSC2; CTRP2	8.4556	10.4752	5.3746	0.4289
KP-3	GDSC1; GDSC2; CTRP2; CCLE	8.5973	10.728	5.338	0.4486
CFPAC-1	GDSC1; GDSC2; CTRP2	8.6299	10.28	5.5119	0.1575
HuP-T4	GDSC1; GDSC2; CTRP2; CCLE	8.7982	13.8005	4.1498	3.9537
PK-59	CTRP2; CCLE	8.847	10.6255	5.4708	0.1665
Capan-2	GDSC1; GDSC2; CTRP2; CCLE	8.9111	10.4999	5.5363	0.0906
PK-45H	CTRP2; CCLE	8.9683	10.9257	5.4103	0.2187
L3.3	CTRP2; CCLE	14.8725	26.6006	1.857	5.8183
-----------


⏷ Show the Full List of 43 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 78 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	10.6156	28.2323	-1.5093	19.4848
HMV-II	GDSC1; GDSC2	1.2407	3.1853	0.1009	5.0301
WM278	GDSC1; GDSC2	1.438	4.8847	-0.5904	8.8454
G-mel	GDSC1; GDSC2	1.6695	4.103	1.2581	18.1815
M14	GDSC1; GDSC2	1.7356	3.3079	0.3863	2.196
WM35	GDSC1; GDSC2	1.8492	4.9783	-0.3335	6.2635
CP50-MEL-B	GDSC1; GDSC2	1.9781	3.4875	1.807	13.8998
Malme-3M	CCLE	2.1657	4.2395	1.5973	9.9679
COLO 783	GDSC1; GDSC2	2.2598	3.1418	2.2066	10.556
Hs 938.T	GDSC1; GDSC2; CCLE	2.288	4.4196	1.7796	11.04
MZ-MEL-7	GDSC1; GDSC2	2.4636	4.1537	2.0759	10.4276
SH-4	GDSC1; GDSC2	2.4695	5.0541	0.0271	2.9751
GAK	GDSC1; GDSC2	2.489	3.8894	0.5281	0.5904
LB2518-MEL	GDSC1; GDSC2	2.5408	3.8362	2.2895	8.914
A-431	GDSC1; GDSC2	2.563	3.6583	2.3825	8.3057
WM88	CTRP2; CCLE	2.637	3.8355	2.6349	22.7074
A-388	GDSC1; GDSC2	2.6586	5.2013	1.785	11.4359
Hs 934.T	CTRP2	2.6846	3.1964	2.6846	22.3835
WM115	GDSC1; GDSC2; CTRP2	2.8119	5.1738	2.7105	21.8809
DJM-1	GDSC1; GDSC2	2.8209	5.5142	1.7846	10.9004
COLO 679	GDSC1; GDSC2; CCLE	2.8293	5.6129	1.5487	8.0757
451Lu	GDSC1; GDSC2	2.8375	4.0895	2.4855	6.6579
Hs 688(A).T	CTRP2	2.8849	3.4941	2.8849	21.0492
SK-MEL-24	GDSC1; GDSC2; CTRP2; CCLE	2.9771	4.9486	2.9201	20.6277
Hs 940.T	GDSC1; GDSC2	2.9788	3.9108	2.7087	4.8377
WM983B	CTRP2; CCLE	2.9894	5.5878	2.823	20.9263
SF8657	CCLE	2.999	5.5613	1.7186	6.9455
CP66-MEL	GDSC1; GDSC2	3.0128	3.8045	2.7915	4.2292
MZ-MEL-2	GDSC1; GDSC2	3.0252	6.4908	1.4839	12.0702
UACC-62	GDSC1; GDSC2; CTRP2	3.1465	5.2182	3.063	19.5906
IGR-37	GDSC1; GDSC2; CTRP2; CCLE	3.1881	4.1494	3.1868	19.0332
WM266-4	CTRP2	3.3168	5.0623	3.2671	18.3395
Hs 895.T	CTRP2; CCLE	3.3353	4.9223	3.3022	18.16
UACC-257	GDSC1; GDSC2; CTRP2	3.4541	5.3696	3.369	17.5472
CHL-1	GDSC1; GDSC2; CCLE	3.4601	5.2798	2.2171	3.1388
IST-MEL1	GDSC1; GDSC2	3.4784	5.2809	0.4116	0.3917
RPMI-7951	GDSC1; GDSC2; CTRP2	3.5752	4.1556	3.5752	16.4501
HT-144	GDSC1; GDSC2; CTRP2; CCLE	3.612	6.7617	3.1643	17.8107
MMAc-SF	GDSC1; GDSC2	3.695	6.2139	2.1739	6.0367
MeWo	GDSC1; GDSC2; CTRP2; CCLE	3.7735	5.2432	3.7301	15.2757
RVH-421	GDSC1; GDSC2; CTRP2; CCLE	3.8381	4.6891	3.8355	14.7075
WM1552C	GDSC1; GDSC2	3.8584	5.411	0.5041	0.1231
VMRC-MELG	GDSC1; GDSC2	3.8622	5.7227	2.5365	3.4795
WT2-iPS	GDSC1; GDSC2; CTRP2; CCLE	4.2069	6.3814	3.9379	13.1984
LB373-MEL-D	GDSC1; GDSC2	4.7506	6.1603	2.8435	0.6368
Hs 695T	CCLE	4.8895	8.0975	1.8005	3.0365
SK-MEL-2	GDSC1; GDSC2; CTRP2; CCLE	7.0278	8.0019	5.7136	0.305
HMCB	CTRP2; CCLE	7.0723	7.9997	5.7338	0.236
SK-MEL-28	GDSC1; GDSC2; CTRP2	7.2664	13.651	3.2052	9.7004
A101D	GDSC1; GDSC2; CTRP2	7.3804	10.2539	4.9215	2.679
A2058	GDSC1; GDSC2; CTRP2; CCLE	7.5848	8.8108	5.6403	0.228
IGR-1	GDSC1; GDSC2; CTRP2	7.5929	9.3135	5.4492	0.6764
K029AX	CTRP2; CCLE	7.6681	9.0357	5.5905	0.2946
Hs 936.T	CTRP2; CCLE	7.6736	15.8883	2.4054	12.1351
IPC-298	GDSC1; GDSC2; CTRP2; CCLE	7.6948	11.9024	4.3501	4.493
IGR-39	CTRP2; CCLE	7.7452	9.4062	5.4816	0.5047
CJM [Human melanoma]	CTRP2	7.746	8.8771	5.6782	0.1235
MDA-MB-435S	CTRP2; CCLE	7.8444	9.3291	5.5529	0.3033
SK-MEL-31	GDSC1; GDSC2; CTRP2; CCLE	7.8944	10.3703	5.1592	1.3287
SK-MEL-30	GDSC1; GDSC2; CTRP2; CCLE	7.904	9.2928	5.5898	0.2165
WM1799	CTRP2; CCLE	7.9212	15.4482	2.8	10.2487
G-361	GDSC1; GDSC2; CTRP2; CCLE	7.9869	12.2672	4.3643	4.0734
Hs 852.T	CTRP2; CCLE	7.9925	9.4752	5.5581	0.2439
COLO 829	GDSC1; GDSC2; CTRP2	8.006	15.009	3.0729	9.0705
SK-MEL-1	GDSC1; GDSC2; CTRP2	8.0272	15.346	2.9245	9.6111
A-375	GDSC1; GDSC2; CTRP2; CCLE	8.1035	10.2242	5.3199	0.7196
Mel JuSo	GDSC1; GDSC2; CTRP2	8.2646	14.1694	3.6497	6.4709
COLO 792	GDSC1; GDSC2; CTRP2	8.3127	11.3974	4.9383	1.6954
WM793	GDSC1; GDSC2; CTRP2; CCLE	8.3319	9.9814	5.5064	0.2321
Hs 839.T	CTRP2	8.3605	23.3962	-0.785	21.047
LOX-IMVI	GDSC1; GDSC2; CTRP2	8.5627	9.7629	5.663	0.036
Hs 944.T	CTRP2; CCLE	8.6377	10.1639	5.5547	0.1093
COLO 800	GDSC1; GDSC2; CTRP2	8.665	21.3642	0.4436	17.1606
Hs 294T	CTRP2; CCLE	9.7369	15.4189	3.959	3.691
Mel Ho	GDSC1; GDSC2; CTRP2; CCLE	10.1531	18.4643	2.8327	7.1679
SK-MEL-5	GDSC1; GDSC2; CTRP2; CCLE	10.4758	19.4078	2.5951	7.6229
SK-MEL-3	GDSC1; GDSC2; CTRP2	11.1783	21.53	2.0465	8.6663
EquiPSC Line K2	GDSC1; GDSC2	1.9032	3.7782	1.6288	15.1803
-----------


⏷ Show the Full List of 78 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
OACM5.1 C	GDSC1; GDSC2	1.4728	3.2894	0.2214	3.7134
ESO-51	GDSC1; GDSC2	1.6851	6.6065	-1.2548	12.2115
ESO-26	GDSC1; GDSC2	2.5001	4.7393	0.1829	2.1127
OACP4 C	GDSC1; GDSC2	2.748	5.1986	0.1163	2.1203
SK-GT-4	GDSC1; GDSC2	2.9487	6.6583	-0.4174	4.6286
KYSE-50	GDSC1; GDSC2	2.9701	4.833	0.3718	0.7948
KYAE-1	GDSC1; GDSC2	3.105	4.8304	0.4292	0.5223
FLO-1	GDSC1; GDSC2	3.1651	5.8113	0.0694	1.852
KYSE-220	GDSC1; GDSC2	3.4094	5.5254	0.2938	0.761
TE-12	GDSC1; GDSC2	3.5635	7.4348	1.4631	10.6595
HCE-4	GDSC1; GDSC2	4.2249	9.9633	0.7204	13.1986
-----------


⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1; GDSC2	3.4322	13.4333	-3.3247	18.1647
-----------

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KP-N-RT-BM-1	GDSC2	0.8165	3.3806	0.5714	26.4171
SJNB-7	GDSC1; GDSC2	1.8421	6.5291	-1.098	10.8926
SJNB-14	GDSC1; GDSC2	1.9408	4.9214	-0.2428	5.5132
SK-N-DZ	GDSC1; GDSC2	1.9709	3.2593	0.5401	1.0284
NB(TU)1	GDSC1; GDSC2	2.0757	5.0005	-0.1905	4.9205
CHP-134	GDSC2	2.1252	3.8133	0.3834	1.6034
SK-N-BE(2)-M17	GDSC1; GDSC2	2.2009	4.0225	0.3333	1.7554
SJNB-13	GDSC1; GDSC2	2.3953	4.5523	0.2077	2.1299
GI-ME-N	GDSC1; GDSC2	2.3977	5.9159	-0.4136	5.5958
SK-N-BE(2)	CTRP2; CCLE	2.4704	4.8398	2.3947	24.0669
IMR-32	CCLE	2.5104	5.1149	1.5112	9.3731
SJNB-12	GDSC1; GDSC2	2.871	4.9855	0.2664	1.2916
IMR-5	GDSC1; GDSC2	3.095	5.0207	0.3533	0.7708
SJNB-17	GDSC1; GDSC2	3.142	12.0766	-1.2062	25.0623
SJNB-5	GDSC1; GDSC2	3.148	4.2678	2.6972	4.3364
GOTO	GDSC1; GDSC2	3.1985	4.7929	0.4797	0.3438
NB69	GDSC1; GDSC2	3.3064	5.6144	0.215	1.1122
KP-N-YS	GDSC1; GDSC2	3.3113	4.6761	2.636	4.2227
NH-12	GDSC1; GDSC2	3.3309	5.0077	0.4532	0.3529
TGW	GDSC1; GDSC2	3.3313	4.9	0.4916	0.2685
SJNB-6	GDSC1; GDSC2	3.4721	5.0884	2.5605	4.2494
CHP-212	GDSC1; GDSC2; CTRP2	3.4915	5.2857	3.4228	17.2413
LA-N-6	GDSC1; GDSC2	3.5382	5.4554	2.4296	4.8767
SJNB-10	GDSC1; GDSC2	3.673	5.1	0.5445	0.1055
SK-N-AS	GDSC1; GDSC2; CTRP2	3.8156	5.7327	3.6895	15.2837
SK-N-MC-IXC	GDSC1; GDSC2	4.0943	5.417	2.8265	1.4269
MHH-NB-11	GDSC1; GDSC2	4.6459	7.5104	2.2013	3.9021
SK-N-FI	GDSC1; GDSC2; CTRP2	6.5274	9.8328	4.5361	5.4661
CHP-126	GDSC1; GDSC2; CTRP2	7.3632	11.5421	4.3018	5.134
Kelly	GDSC1; GDSC2; CTRP2	7.9871	9.4591	5.5618	0.2391
KP-N-SI9s	CTRP2; CCLE	8.0848	9.5216	5.5769	0.1882
NH-6	CTRP2	8.1515	9.7919	5.505	0.2873
KP-N-YN	GDSC1; GDSC2; CTRP2	8.3367	9.9867	5.5063	0.231
NB1	GDSC1; GDSC2; CTRP2	8.4322	9.7347	5.6282	0.0697
SiMa	GDSC1; GDSC2; CTRP2; CCLE	8.5603	10.3536	5.4602	0.2437
SK-N-SH	GDSC1; GDSC2; CTRP2; CCLE	8.8028	10.6294	5.4532	0.1971
-----------


⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuCC-T1	GDSC1; GDSC2; CTRP2; CCLE	4.3925	7.1185	3.8664	12.942
HuH-28	CTRP2	7.7945	9.3232	5.5346	0.3602
SNU-1079	CTRP2	8.0383	15.4865	2.8642	9.8253
SNU-1196	CTRP2	8.0694	14.1082	3.5497	7.1244
SNU-478	CTRP2	8.2506	9.8791	5.512	0.2454
SNU-308	CTRP2	8.3606	9.8054	5.579	0.1275
SNU-869	CTRP2	8.4112	15.7386	2.9997	8.7651
SNU-245	CTRP2	9.2183	11.543	5.285	0.3425
-----------


⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
DU4475	GDSC1; GDSC2; CTRP2	0.9772	2.0592	0.9772	33.7584
HCC2157	GDSC1; GDSC2	0.9881	3.3592	-0.1895	7.5652
Evsa-T	GDSC1; GDSC2	1.1664	1.8781	1.1656	17.5466
OCUB-M	GDSC1; GDSC2	2.389	4.005	2.0607	9.0767
CAL-120	GDSC1; GDSC2	2.6591	3.8064	2.4262	6.4471
AU565	GDSC1; GDSC2; CTRP2; CCLE	2.7354	4.0717	2.7302	22.0625
ZR-75-30	GDSC1; GDSC2; CTRP2; CCLE	2.7735	4.7176	2.7306	21.9357
UACC-893	GDSC1; GDSC2	2.7941	5.092	1.966	9.8979
COLO 824	GDSC1; GDSC2	2.9226	4.5425	2.3536	6.0016
UACC-812	GDSC2; CCLE	2.9477	5.866	1.5232	7.9137
MFM-223	GDSC1; GDSC2	3.0205	5.125	2.1583	6.7258
HCC1569	GDSC1; GDSC2; CCLE	3.0548	5.4675	2.0191	7.5444
MDA-MB-330	GDSC1; GDSC2	3.0555	5.343	2.0816	8.3632
BT-483	GDSC1; GDSC2	3.1682	5.3724	2.1659	6.3087
SK-BR-3	CCLE	3.2673	4.9819	2.222	3.5954
MDA-MB-436	GDSC1; GDSC2; CCLE	3.4331	4.8702	2.6384	3.2565
EFM-19	GDSC1; GDSC2; CCLE	3.4454	5.5371	2.3155	4.8844
MDA-MB-415	GDSC1; GDSC2; CCLE	3.5691	5.894	2.2357	5.0216
YMB-1-E	GDSC2	3.5911	5.7727	2.313	5.647
CAL-148	GDSC2	3.6147	5.0068	2.7093	2.5189
MRK-nu-1	GDSC1; GDSC2	3.6299	4.9796	2.7337	2.3673
MDA-MB-175-VII	GDSC1; GDSC2; CCLE	3.6894	5.5745	2.232	2.653
HCC1599	GDSC2	3.7775	5.3753	2.6456	3.1138
HCC70	GDSC1; GDSC2; CCLE	3.8244	6.5752	2.0927	5.2215
BT-20	GDSC1; GDSC2; CTRP2; CCLE	3.8763	5.5202	3.798	14.7118
HCC202	GDSC1	3.9143	6.0533	0.3011	0.5948
CAL-85-1	GDSC1; GDSC2; CTRP2; CCLE	3.9285	5.7373	3.8113	14.5004
HCC1187	GDSC1; GDSC2; CCLE	4.1705	6.4655	2.3886	3.1221
KPL-1	CTRP2	4.4323	5.9948	4.2984	11.2068
Hs 739.T	CCLE	4.5571	8.3586	1.4806	5.0621
MDA-MB-157	GDSC1; GDSC2; CCLE	4.5769	6.6662	2.5436	1.8326
MDA-MB-453	GDSC1; GDSC2; CTRP2; CCLE	4.6566	7.9939	3.762	12.6569
HCC1419	GDSC1; GDSC2; CTRP2	5.5849	12.8395	2.2567	16.5642
MDA-MB-468	GDSC1; GDSC2; CTRP2; CCLE	6.8906	8.6488	5.3616	1.5892
Hs 578T	GDSC1; GDSC2; CTRP2; CCLE	7.1294	12.8909	3.4779	8.8282
HCC1428	GDSC1; GDSC2; CTRP2	7.3231	13.6724	3.2364	9.4838
JIMT-1	GDSC1; GDSC2; CTRP2	7.4461	9.1224	5.4571	0.751
MDA-MB-361	GDSC1; GDSC2; CTRP2	7.5984	11.3823	4.5328	3.9052
HMC-1-8	CTRP2; CCLE	7.7647	9.0858	5.6107	0.2229
BT-474	GDSC1; GDSC2; CTRP2; CCLE	7.8139	9.2571	5.5673	0.2863
ZR-75-1	CTRP2	7.8601	9.3213	5.5621	0.2799
EFM-192A	GDSC1; GDSC2; CTRP2	7.9879	14.8652	3.1298	8.8768
HCC1500	GDSC1; GDSC2; CTRP2	7.9904	15.315	2.9137	9.7078
CAL-51	GDSC1; GDSC2; CTRP2	8.0093	10.0284	5.3548	0.6821
BT-549	GDSC1; GDSC2; CTRP2; CCLE	8.0762	9.6093	5.542	0.2461
HCC2218	GDSC1; GDSC2; CTRP2	8.2032	10.4499	5.2756	0.7785
MDA-MB-231	GDSC1; GDSC2; CTRP2	8.2674	14.9198	3.2947	7.838
HCC38	GDSC1; GDSC2; CTRP2	8.3201	10.1815	5.4288	0.3721
HDQ-P1	GDSC1; GDSC2; CTRP2; CCLE	8.3694	10.2342	5.4291	0.354
HCC1937	GDSC1; GDSC2; CTRP2	8.4564	10.39	5.4065	0.3666
HCC1143	GDSC1; GDSC2; CTRP2	8.5377	12.5674	4.5516	2.7918
HCC1954	GDSC1; GDSC2; CTRP2; CCLE	8.5474	14.0079	3.9049	5.1404
HCC1806	GDSC1; GDSC2; CTRP2; CCLE	8.5621	12.263	4.6978	2.2707
HCC1395	GDSC1; GDSC2; CTRP2	8.6351	10.7949	5.3285	0.4533
T-47D	GDSC1; GDSC2; CTRP2; CCLE	8.6352	10.4763	5.4448	0.2479
MCF-7	GDSC1; GDSC2; CTRP2; CCLE	8.7743	10.4249	5.5139	0.1304
CAMA-1	GDSC1; GDSC2; CTRP2; CCLE	9.258	18.8134	2.0987	10.8763
BT 131	CTRP2	2.3379	4.3837	2.3038	24.8078
BT147	CTRP2	2.4839	6.1173	2.1386	24.9199
BT 428	CTRP2	2.5939	3.1737	2.5939	22.9874
BT 248	CTRP2	2.866	4.8372	2.8156	21.3452
BT 330	CTRP2	2.9289	3.7835	2.9286	20.7568
BT 245	CTRP2	2.9888	4.624	2.9647	20.4379
BT 286	CTRP2	3.2427	5.5149	3.1134	19.1096
BT 416	CTRP2	3.4325	6.3605	3.1017	18.5701
BT 482	CTRP2	3.6035	4.7544	3.5937	16.2945
BT 422	CTRP2	3.698	5.6133	3.5873	16.0125
BT 271	CTRP2	3.804	5.1403	3.7742	15.0265
BT 440	CTRP2	3.8365	7.2164	3.2375	16.895
BT 172	CTRP2	3.8837	5.1689	3.8553	14.4908
BT 498	CTRP2	3.9249	6.3172	3.6515	15.0881
BT 504	CTRP2	4.2108	6.6475	3.8514	13.5093
BT 216	CTRP2	4.5323	7.4599	3.8708	12.5479
BT 444	CTRP2	4.6178	8.137	3.6581	13.1707
BT 320	CTRP2	4.8999	7.8164	4.0873	10.7392
BT 340	CTRP2	5.0158	7.8723	4.1768	10.0905
BT 359	CTRP2	5.6329	8.7633	4.3284	8.0484
BT 333	CTRP2	6.0696	9.3812	4.397	6.8757
BT 328	CTRP2	6.7297	9.2418	4.9745	3.3339
BT 232	CTRP2	7.1586	11.4413	4.2087	5.8094
BT 112	CTRP2	7.3483	8.4092	5.6938	0.2091
BT 139	CTRP2	7.4693	8.9816	5.5252	0.5448
BT164	CTRP2	7.5124	8.5886	5.6928	0.159
BT 159	CTRP2	7.6144	8.8058	5.6538	0.1944
BT 179	CTRP2	7.7594	8.8333	5.6983	0.096
BT 228	CTRP2	7.8191	9.0033	5.6609	0.131
BT 224	CTRP2	8.0298	9.4778	5.5716	0.2107
BT 145	CTRP2	8.2676	9.8015	5.5462	0.1886
BT 231	CTRP2	8.2779	10.2561	5.3834	0.4821
BT 187	CTRP2	8.3461	9.8336	5.5639	0.1481
BT 239	CTRP2	8.4511	9.8395	5.5995	0.0923
-----------


⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	7.2226	9.7899	5.0387	2.4211
-----------

Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
GI-1	GDSC1; GDSC2	1.8781	6.4659	-1.0401	10.4616
D-423MG	GDSC1; GDSC2	2.0213	4.8906	1.299	16.5646
MOG-G-UVW	GDSC1; GDSC2	2.4047	5.8691	-0.3871	5.4279
D-336MG	GDSC1; GDSC2	2.4407	3.7284	2.2251	9.6775
SK-MG-1	GDSC1; GDSC2	2.4712	5.8694	-0.3451	5.0595
PFSK-1	GDSC1; GDSC2	2.5062	8.9382	-1.7946	13.1884
D-566MG	GDSC1; GDSC2	2.5943	4.038	2.261	8.8664
H4	GDSC1; GDSC2; CCLE	2.8913	5.167	1.8247	6.4658
Onda 10	GDSC1; GDSC2	3.0218	4.3398	2.5454	5.6617
D-245MG	GDSC2	3.0276	5.8833	1.7884	10.5927
D-263MG	GDSC1; GDSC2	3.0327	4.9306	0.3611	0.7872
D-502MG	GDSC1; GDSC2	3.0665	4.8021	2.3595	6.6415
CAS-1	GDSC1; GDSC2; CTRP2; CCLE	3.2056	4.2638	3.2029	18.9216
LNZTA3WT4	GDSC1	3.2144	5.0075	0.4077	0.655
KINGS-1	GDSC1; GDSC2	3.2318	5.064	0.3938	0.5568
SF126	GDSC1; GDSC2; CTRP2; CCLE	3.2782	5.0836	3.2234	18.6145
Hs 683	GDSC1; GDSC2; CTRP2; CCLE	3.2895	5.1663	3.2242	18.5751
M059J	GDSC1; GDSC2; CCLE	3.3056	4.8395	2.3209	2.9056
LN-405	GDSC1; GDSC2	3.3426	4.7377	0.552	0.1572
SF268	GDSC1; GDSC2; CTRP2	3.3499	4.8872	3.3208	18.0492
AM-38	GDSC1; GDSC2	3.4505	5.7317	0.2325	0.9397
D-392MG	GDSC1; GDSC2	3.4516	6.8906	-0.2403	2.9729
D-247MG	GDSC1; GDSC2	3.4797	6.156	2.0341	7.438
SW1088	GDSC1; GDSC2; CTRP2; CCLE	3.5605	4.4918	3.5581	16.5561
GaMG	GDSC1; GDSC2; CTRP2	3.5669	4.671	3.5597	16.5296
KNS-60	CTRP2; CCLE	3.6296	4.6924	3.5803	10.2788
D-542MG	GDSC1; GDSC2	3.6539	6.3941	2.053	6.8707
KS-1 [Human Krukenberg tumour]	GDSC1; GDSC2	3.7711	5.8302	0.3264	0.4765
KALS-1	GDSC1; GDSC2; CTRP2; CCLE	3.8971	5.3237	3.8512	14.461
Daoy	GDSC1; GDSC2; CTRP2; CCLE	4.0513	5.8789	3.9122	13.7609
SF539	GDSC1; GDSC2; CTRP2	4.2286	5.8723	4.107	12.5184
KNS-42	GDSC1; GDSC2; CTRP2; CCLE	4.3501	5.6708	4.2823	11.5196
KNS-81-FD	GDSC1; GDSC2	4.4211	6.539	2.5109	2.5903
U-251MG	GDSC1; GDSC2; CTRP2	4.461	5.9815	4.3331	10.9944
GB-1	GDSC1; GDSC2; CTRP2; CCLE	4.6496	6.5016	4.3768	10.2742
MOG-G-CCM	GDSC1; GDSC2; CCLE	4.8355	9.4257	1.1578	6.0415
Onda 11	GDSC1; GDSC2	5.5187	7.6931	2.5836	0.9887
TM-31	CTRP2	7.0598	8.3912	5.5702	0.6926
D283 Med	GDSC1; GDSC2; CTRP2	7.1446	8.6668	5.4968	0.8582
KNS-81	CTRP2; CCLE	7.337	8.2873	5.7339	0.1416
LN-18	GDSC1; GDSC2; CTRP2; CCLE	7.3658	8.1924	5.7781	0.0737
DK-MG	GDSC1; GDSC2; CTRP2; CCLE	7.3741	8.7672	5.5671	0.4892
SNU-201	CTRP2	7.4809	8.8738	5.573	0.4167
SNU-1105	CTRP2	7.603	21.6081	-0.4797	21.5148
42-MG-BA	GDSC1; GDSC2; CTRP2	7.6336	10.3016	5.0489	1.9345
SNU-466	CTRP2	7.6956	8.5766	5.7632	0.0431
SW1783	GDSC1; GDSC2; CTRP2	7.6976	10.417	5.0336	1.9251
SNU-626	CTRP2	7.7214	8.8645	5.6735	0.1353
U-118MG	GDSC1; GDSC2; CTRP2; CCLE	7.7408	10.7777	4.8974	2.3664
8-MG-BA	GDSC1; GDSC2; CTRP2	7.7734	10.0497	5.233	1.1917
CCF-STTG1	CTRP2	7.8117	9.1296	5.6131	0.2046
YKG-1	GDSC1; GDSC2; CTRP2; CCLE	7.8956	9.309	5.5807	0.2346
SF295	GDSC1; GDSC2; CTRP2; CCLE	7.9335	9.4857	5.5308	0.3139
GMS-10	CTRP2; CCLE	7.9874	9.161	5.6672	0.0924
SNU-738	CTRP2	8.0108	9.3995	5.5924	0.1835
GOS-3	CTRP2	8.0273	9.5941	5.5284	0.2857
KG-1-C	CTRP2	8.0606	9.5067	5.573	0.2002
SNU-489	CTRP2	8.1145	9.2491	5.6818	0.0619
A-172	GDSC1; GDSC2; CTRP2; CCLE	8.1282	9.6107	5.5615	0.2004
DBTRG-05MG	GDSC1; GDSC2; CTRP2; CCLE	8.1874	10.0497	5.4238	0.4334
M059K	CTRP2	8.2216	9.4525	5.6504	0.0758
NMC-G1	GDSC1; GDSC2; CTRP2	8.2729	9.8468	5.5321	0.208
LN-229	GDSC1; GDSC2; CTRP2; CCLE	8.2836	9.6829	5.5936	0.1242
T98G	GDSC1; GDSC2; CTRP2; CCLE	8.4119	16.5699	2.6002	10.267
YH-13	GDSC1; GDSC2; CTRP2	8.4985	9.8275	5.6199	0.0691
ONS-76	GDSC1; GDSC2; CTRP2; CCLE	8.5632	10.063	5.5628	0.1122
Becker	GDSC1; GDSC2; CTRP2	8.5775	10.0611	5.5685	0.1044
SNB-75	GDSC1; GDSC2; CTRP2	8.8385	10.6973	5.4426	0.2036
U-87MG ATCC	GDSC1; GDSC2; CTRP2; CCLE	9.9339	19.5808	2.1781	9.7063
-----------


⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ETK-1	GDSC1; GDSC2	1.9337	4.1138	0.1354	3.2802
TGBC1TKB	GDSC1; GDSC2	2.4914	4.7703	0.1647	2.2171
TGBC24TKB	GDSC1; GDSC2	2.8326	4.8449	0.3053	1.1653
-----------

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEC-1-B	CCLE	2.5172	5.3787	1.3876	10.0151
HEC-151	CTRP2; CCLE	2.82	4.0157	2.8171	21.4912
EFE-184	CTRP2; CCLE	3.4492	4.3143	3.4481	17.2935
MFE-280	GDSC1; GDSC2; CCLE	3.7891	5.9942	2.0985	3.1483
KLE	GDSC1; GDSC2; CCLE	4.4793	6.5512	2.253	1.4911
TEN	CCLE	4.5049	8.2678	1.4898	5.1019
JHUEM-1	CTRP2	4.5191	5.601	4.4765	10.3069
HEC-1-A	CTRP2; CCLE	4.576	5.6488	4.53	9.9397
EN	GDSC1; GDSC2; CTRP2; CCLE	7.4413	9.5433	5.2762	1.3308
HEC-265	CTRP2; CCLE	7.4518	8.3741	5.7462	0.0962
HEC-108	CTRP2	7.6897	9.3324	5.4859	0.5231
HEC-251	CTRP2; CCLE	7.8906	9.3218	5.5741	0.2477
HEC-59	CTRP2; CCLE	7.9756	9.1013	5.6834	0.0778
RL95-2	GDSC1; GDSC2; CTRP2; CCLE	8.0599	9.4233	5.6024	0.1575
JHUEM-7	CTRP2	8.0777	9.8824	5.4413	0.4419
HEC-6	CTRP2; CCLE	8.2068	9.6997	5.5595	0.1839
AN3-CA	GDSC1; GDSC2; CTRP2; CCLE	8.2743	9.9085	5.5106	0.2411
ESS-1	GDSC1; GDSC2; CTRP2	8.2975	10.0687	5.4614	0.3186
MFE-319	GDSC1; GDSC2; CTRP2	8.2979	9.6949	5.5946	0.1206
JHUEM-2	CTRP2	8.4039	10.3558	5.398	0.4017
MFE-296	GDSC1; GDSC2; CTRP2	8.5956	10.1513	5.5441	0.1267
HEC-50B	CTRP2	13.7955	27.6657	0.8061	9.6766
Ishikawa (Heraklio) 02 ER-	CTRP2	7.6926	9.1246	5.5672	0.3331
-----------


⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LB2241-RCC	GDSC1; GDSC2	0.6846	7.4813	-1.2227	33.7919
A-704	GDSC1; GDSC2	1.9725	5.5348	-0.5169	7.0994
KTCTL-140	GDSC1; GDSC2	2.3271	3.2873	2.2455	10.0514
UO-31	GDSC1; GDSC2; CTRP2	2.3973	3.345	2.3971	24.2984
SW156	GDSC1; GDSC2	2.899	4.5844	2.311	7.4784
NCC010	GDSC1; GDSC2	2.91	4.7698	2.2314	7.9201
A-498	GDSC1; GDSC2	3.0284	4.5282	0.5096	0.3421
KTCTL-13	GDSC1; GDSC2	3.0542	4.7108	2.3934	6.4748
SW13	GDSC1; GDSC2	3.1534	5.081	0.355	0.7254
LB996-RCC	GDSC2	3.2532	6.089	-0.0026	2.0821
KTCTL-195	GDSC1; GDSC2	3.273	5.0621	0.411	0.4863
SN12C	GDSC1; GDSC2	3.5768	5.2002	0.4767	0.2233
NCC021	GDSC1; GDSC2	3.6115	5.2045	2.6097	3.6053
HA7-RCC	GDSC1; GDSC2	3.6277	5.2986	2.5754	3.7733
CAL-54	GDSC1; GDSC2; CTRP2	3.6449	5.0196	3.6185	16.0746
TUHR14TKB	CTRP2	3.6944	7.4039	3.0131	18.1466
KTCTL-26A	GDSC1; GDSC2	3.8194	5.597	2.5676	3.3875
TK-10	GDSC1; GDSC2	3.8559	6.2125	0.2198	0.7257
KTCTL-21	GDSC1; GDSC2	3.8854	6.7913	2.0315	6.4366
KTCTL-1M	GDSC1; GDSC2	4.301	6.6446	2.3885	3.4716
VMRC-RCZ	GDSC1; GDSC2; CTRP2; CCLE	4.3468	5.5656	4.2971	11.4788
BFTC-909	GDSC1; GDSC2; CTRP2; CCLE	4.4757	5.1485	4.4721	10.4628
KMRC-2	CTRP2; CCLE	4.4788	7.4559	3.8169	12.9012
LB1047-RCC	GDSC1; GDSC2	4.5066	7.0612	2.3232	3.4707
RXF 393L	GDSC1; GDSC2	4.9066	10.034	1.1771	9.1363
BB65-RCC	GDSC1; GDSC2	5.3291	15.2832	-1.0795	18.9716
TUHR10TKB	CTRP2	7.4074	8.538	5.6698	0.2343
KMRC-1	GDSC1; GDSC2; CTRP2; CCLE	7.8499	9.0379	5.6601	0.1255
KMRC-20	GDSC1; GDSC2; CTRP2	7.9992	10.156	5.2992	0.8368
786-O	GDSC1; GDSC2; CTRP2; CCLE	8.0113	12.82	4.1219	4.9733
TUHR4TKB	CTRP2	8.0465	9.2595	5.6544	0.0966
RCC10RGB	GDSC1; GDSC2; CTRP2	8.1939	9.4491	5.6418	0.0874
SNU-1272	CTRP2	8.2174	9.663	5.5763	0.1584
Caki-2	CTRP2; CCLE	8.2276	9.4815	5.6426	0.082
OS-RC-2	GDSC1; GDSC2; CTRP2	8.3123	10.1349	5.4429	0.3477
ACHN	GDSC1; GDSC2; CTRP2	8.33	9.8323	5.5585	0.1582
VMRC-RCW	GDSC1; GDSC2; CTRP2; CCLE	8.4341	10.0898	5.5065	0.2063
KMRC-3	CTRP2	8.4905	10.2134	5.4837	0.2259
769-P	GDSC1; GDSC2; CTRP2; CCLE	8.661	10.0295	5.608	0.0617
Caki-1	GDSC1; GDSC2; CTRP2	9.1509	10.9842	5.456	0.1327
-----------


⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 60 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW1463	GDSC1; GDSC2	2.4046	3.948	0.4671	0.895
GP5d	GDSC1; GDSC2	2.4924	4.2361	0.3916	1.1302
COLO 320	CTRP2; CCLE	2.6435	4.7224	2.5928	22.8283
CL-11	GDSC1; GDSC2; CTRP2	2.6702	5.3545	2.5249	22.977
C2BBe1	GDSC1; GDSC2; CCLE	2.6899	5.3195	1.5726	8.3123
SW837	GDSC1; GDSC2	2.8579	4.8422	0.3181	1.0898
SW1116	GDSC1; GDSC2; CTRP2	2.9007	4.8832	2.847	21.1254
NCI-H747	GDSC1; GDSC2; CTRP2; CCLE	3.0184	4.4604	3.0055	20.203
SNU-C5	GDSC1; GDSC2; CTRP2	3.0655	5.4883	2.9266	20.3231
COLO 320HSR	GDSC1; GDSC2	3.1073	9.0549	-1.4356	9.9508
DiFi	GDSC1; GDSC2	3.1724	5.1074	0.353	0.7198
SNU-175	GDSC2	3.1814	5.0718	0.3702	0.6582
SNU-C2B	GDSC1; GDSC2; CCLE	3.2226	5.1683	2.0954	4.2577
SW626	GDSC1; GDSC2	3.3029	6.0416	0.0415	1.8301
HCC2998	GDSC1; GDSC2	3.7382	5.5357	0.4187	0.2838
CaR-1	GDSC1; GDSC2	3.8496	5.7903	0.3704	0.3452
SW403	CCLE	4.3484	6.8858	2.0326	2.6865
SNU-81	GDSC1; GDSC2	4.6435	20.2798	-4.0824	29.4171
SW480	CCLE	5.4128	8.4931	1.9082	1.9806
SNU-283	GDSC2	5.5049	7.0786	2.8087	0.3333
OUMS-23	CTRP2	6.9814	9.5736	4.9863	2.9308
SW948	GDSC1; GDSC2; CTRP2	7.575	8.7354	5.664	0.1887
HCC-56	CTRP2; CCLE	7.6474	8.5937	5.7407	0.0686
COLO201	CTRP2; CCLE	7.6718	8.9504	5.6235	0.2296
LS1034	GDSC1; GDSC2; CTRP2	7.7476	9.5273	5.435	0.6217
DLD-1	CTRP2	7.7644	8.8818	5.6833	0.1132
SNU-1033	CTRP2	7.7705	10.4228	5.0713	1.7254
COLO205	GDSC1; GDSC2; CTRP2; CCLE	7.7961	9.0421	5.6385	0.1683
HCT 8	CTRP2	7.8019	9.0505	5.6378	0.168
SNU-503	CTRP2	7.8089	11.9207	4.4143	4.0993
T84	GDSC1; GDSC2; CTRP2; CCLE	7.864	9.8521	5.3586	0.7573
HCT 116	GDSC1; GDSC2; CTRP2; CCLE	7.892	13.1208	3.9022	5.9871
RCM-1 [Human ESC]	GDSC1; GDSC2; CTRP2	7.9225	9.588	5.4878	0.407
HT115	GDSC1; GDSC2; CTRP2	7.9284	9.0676	5.6782	0.09
SNU-C4	CTRP2	7.9434	8.9516	5.7227	0.0484
HT-29	GDSC1; GDSC2; CTRP2; CCLE	7.9625	9.4556	5.5535	0.2614
KM12	GDSC1; GDSC2; CTRP2	7.9839	9.5382	5.5316	0.2943
NCI-H508	GDSC1; GDSC2; CTRP2	8.0103	9.5057	5.5539	0.2456
LS180	GDSC1; GDSC2; CTRP2	8.098	9.8318	5.4687	0.3757
COLO 678	GDSC1; GDSC2; CTRP2; CCLE	8.1073	10.0125	5.4041	0.5118
LS411N	GDSC1; GDSC2; CTRP2	8.1141	9.6135	5.5552	0.2139
HCT 15	GDSC1; GDSC2; CTRP2; CCLE	8.2148	9.6331	5.5859	0.1465
HT-55	GDSC1; GDSC2; CTRP2	8.2249	9.3152	5.6974	0.0406
NCI-H716	GDSC1; GDSC2; CTRP2	8.2562	9.8874	5.5112	0.2452
GP2d	CTRP2	8.2629	9.867	5.521	0.2276
MDST8	GDSC1; GDSC2; CTRP2	8.2717	9.5496	5.635	0.0833
CW-2	GDSC1; GDSC2; CTRP2	8.2849	10.0426	5.4659	0.3144
LS123	GDSC1; GDSC2; CTRP2; CCLE	8.3229	10.2109	5.419	0.3902
SK-CO-1	GDSC1; GDSC2; CTRP2; CCLE	8.3328	9.7284	5.5955	0.1138
SNU-61	GDSC1; GDSC2; CTRP2	8.3331	9.9224	5.5279	0.1994
SNU-C2A	CTRP2; CCLE	8.3794	11.8891	4.762	2.2184
CCK-81	GDSC1; GDSC2; CTRP2	8.5018	10.086	5.5328	0.1564
SW48	GDSC1; GDSC2; CTRP2; CCLE	8.5271	10.1361	5.5246	0.1617
SNU-C1	GDSC1; GDSC2; CTRP2	8.5967	15.7503	3.1182	8.0595
SW620	GDSC1; GDSC2; CTRP2; CCLE	8.655	10.0368	5.6036	0.0654
LoVo	GDSC1; GDSC2; CTRP2	8.7027	10.6299	5.4155	0.2755
LS513	GDSC1; CTRP2; CCLE	8.7282	10.6292	5.4255	0.2535
SW1417	GDSC1; GDSC2; CTRP2	8.852	10.4676	5.5267	0.1064
SNU-407	GDSC1; GDSC2; CTRP2	8.9813	11.0304	5.3782	0.2609
RKO	GDSC1; GDSC2; CTRP2; CCLE	10.7701	21.9864	1.5834	10.6465
-----------


⏷ Show the Full List of 60 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1; GDSC2	2.2616	6.5044	-0.7849	8.0595
-----------

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-182	CTRP2; CCLE	2.1406	5.3901	1.9432	26.6816
JHH-5	CTRP2	2.5002	3.7814	2.4975	23.6211
Huh-7	GDSC1; GDSC2	2.6738	5.0777	0.1292	2.1518
Hep-G2/C3A	GDSC1; GDSC2	2.7272	3.9019	0.619	0.208
Li-7	CTRP2	2.7407	5.4871	2.5744	22.5811
HuH-6	CTRP2	2.8119	5.3974	2.67	22.0219
SNU-449	GDSC1; GDSC2; CTRP2; CCLE	3.2108	4.7979	3.1828	18.972
JHH-7	GDSC1; GDSC2	3.3895	5.7132	0.2132	1.0538
SNU-761	CTRP2	3.46	4.0965	3.4575	11.3177
SNU-886	CTRP2	3.9299	5.1868	3.9022	14.1804
HLE	GDSC1; GDSC2; CCLE	5.6289	7.8965	2.2451	0.6501
JHH-6	GDSC1; GDSC2; CTRP2; CCLE	6.7599	8.3119	5.4369	1.4577
JHH-2	GDSC1; GDSC2; CTRP2; CCLE	7.2648	10.1695	4.8886	2.946
JHH-4	GDSC1; GDSC2; CTRP2; CCLE	7.4493	10.1832	4.9955	2.3222
PLC/PRF/5	CTRP2; CCLE	7.5483	9.2803	5.4416	0.7265
SK-HEP-1	GDSC1; GDSC2; CTRP2; CCLE	7.5922	16.3312	2.1271	13.3
SNU-387	GDSC1; GDSC2; CTRP2	7.7177	11.401	4.5989	3.5034
Hep 3B2.1-7	GDSC1; GDSC2; CTRP2; CCLE	7.8	13.8143	3.5074	7.6741
JHH-1	GDSC1; GDSC2; CTRP2	7.9183	9.0418	5.6835	0.0861
HuH-1	GDSC1; GDSC2; CTRP2; CCLE	8.0044	9.4856	5.5589	0.2389
HLF	CTRP2; CCLE	8.2811	9.5704	5.6312	0.0855
SNU-423	GDSC1; GDSC2; CTRP2; CCLE	8.4273	10.2728	5.4379	0.3187
SNU-398	GDSC1; GDSC2; CTRP2	8.4756	10.2228	5.4747	0.2434
SNU-878	CTRP2	8.5206	10.27	5.4749	0.2315
SNU-475	CTRP2	8.587	9.9425	5.6118	0.0661
Hep-G2	CTRP2; CCLE	10.7093	26.8422	-0.7703	17.5497
-----------


⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 225 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H1703	GDSC1; GDSC2; CTRP2	0.666	4.2559	0.5489	36.1988
NCI-H835	GDSC1; GDSC2	1.5771	3.5717	0.1576	3.871
CPC-N	GDSC1; GDSC2	1.741	4.8326	-0.3393	6.5461
NCI-H1304	GDSC1	1.7458	3.4738	0.3156	3.2188
Ms-1	GDSC1; GDSC2	1.7646	4.62	-0.2192	5.756
COR-L279	GDSC1; GDSC2	1.7819	3.7563	0.2063	3.1547
NCI-H720	GDSC1; GDSC2	1.8646	3.4462	0.4002	1.9
Lu-139	GDSC1	2.0366	4.2112	0.154	3.7196
NCI-H524	GDSC1; GDSC2	2.0463	5.2778	-0.3423	5.8869
NCI-H64	GDSC1; GDSC2	2.0715	4.3075	0.1309	3.0565
DMS 454	CTRP2	2.0887	4.7752	1.9961	26.6669
RERF-LC-Sq1	GDSC1; GDSC2	2.0953	5.0717	-0.2114	5.0048
Lu-135	GDSC1; GDSC2	2.1077	4.4882	0.0698	3.3406
A-427	GDSC1; GDSC2	2.1681	5.9381	0.961	17.954
NCI-H2795	GDSC1; GDSC2	2.2036	4.4189	0.1589	2.6781
DMS 53	GDSC1; GDSC2; CTRP2	2.214	3.0813	2.214	25.5186
NCI-H2171	GDSC2	2.2147	3.3121	2.1162	11.6295
NCI-H211	GDSC1; GDSC2; CTRP2; CCLE	2.2528	4.3762	2.2154	25.3858
NCI-H1648	GDSC1; GDSC2; CCLE	2.3545	4.1087	1.8458	7.8536
NCI-H1385	CTRP2	2.3919	3.7646	2.3883	24.3452
NCI-H146	GDSC1; GDSC2; CTRP2	2.4049	4.7749	2.3335	24.4885
NCI-H1688	GDSC1; GDSC2	2.4649	4.3215	0.3428	1.3791
NCI-H2029	GDSC1; GDSC2	2.4651	4.7482	1.8109	11.9593
COR-L311	GDSC2	2.4854	6.1634	-0.4737	5.7746
SK-MES-1	GDSC1; GDSC2; CTRP2	2.5233	3.4157	2.5232	23.4584
NCI-H3122	GDSC1; GDSC2	2.5242	5.9939	-0.3699	5.1035
NCI-H2087	GDSC1; GDSC2; CTRP2; CCLE	2.6261	5.2847	2.4905	23.2368
NCI-H1781	GDSC1; GDSC2	2.6482	4.0798	0.5229	0.5013
COLO 677	CCLE	2.679	5.278	1.5836	8.5121
NCI-H1993	GDSC1; GDSC2	2.7229	5.1377	0.1292	2.0887
NCI-H2461	GDSC1; GDSC2	2.7989	5.4828	0.0207	2.53
NCI-H810	GDSC1; GDSC2; CTRP2; CCLE	2.8131	4.3437	2.7997	21.5723
COR-L303	GDSC2	2.8544	4.999	2.0678	9.4123
DV-90	CTRP2	2.9217	5.7419	2.7141	21.5225
NCI-H2369	GDSC1; GDSC2	2.9756	4.4886	0.5034	0.3815
NCI-H2804	GDSC1; GDSC2	2.9858	4.5036	2.432	6.4632
NCI-H209	GDSC1; GDSC2	2.9888	5.1825	0.2421	1.2811
RERF-LC-KJ	GDSC1; GDSC2	2.992	4.4808	0.5127	0.3503
NCI-H187	GDSC1	3.0074	4.1262	0.6421	0.1223
NCI-H1155	GDSC1; GDSC2; CTRP2	3.011	4.4309	2.9993	20.248
NCI-H1048	GDSC1; GDSC2; CCLE	3.0376	4.4791	2.2916	3.6455
NCI-H1437	GDSC1; GDSC2	3.0508	4.401	2.5426	5.5838
HCC2935	CTRP2; CCLE	3.0718	4.0389	3.0708	19.8071
IST-SL1	GDSC1; GDSC2	3.1011	5.2324	2.1769	7.6442
LC-1/sq	GDSC1; GDSC2	3.1391	5.7667	0.0751	1.8546
COLO 668	GDSC1; GDSC2; CTRP2	3.1419	5.5122	3.0046	19.8088
LB647-SCLC	GDSC1; GDSC2	3.1667	4.2032	2.7461	3.9809
NCI-H2373	GDSC1; GDSC2	3.1755	5.0311	0.3831	0.6213
NCI-H82	GDSC1; GDSC2	3.1758	4.7269	0.4947	0.3176
NCI-H2810	GDSC1; GDSC2	3.211	4.5459	2.6152	4.6417
ABC-1	GDSC1; GDSC2	3.215	4.7825	2.5007	5.3278
NCI-H1581	GDSC1; GDSC2; CTRP2; CCLE	3.2218	4.907	3.1841	18.9317
NCI-H358	GDSC1; GDSC2; CTRP2; CCLE	3.2276	4.4747	3.2197	18.7924
Calu-3	GDSC1; GDSC2; CTRP2; CCLE	3.2286	4.2219	3.2268	18.7654
NCI-H1573	GDSC1; GDSC2; CTRP2; CCLE	3.2407	6.5669	2.8275	20.1456
Lu-165	GDSC1; GDSC2	3.2417	4.5647	0.5754	0.1442
NCI-H2066	GDSC1; GDSC2	3.2474	4.9128	0.4553	0.3824
HCC44	GDSC1; GDSC2; CTRP2	3.2553	5.3691	3.1548	18.9246
NCI-H2106	CTRP2	3.2664	4.7791	3.2425	18.5878
NCI-H1694	GDSC1; GDSC2; CTRP2; CCLE	3.2744	5.0084	3.2286	18.6088
HCC33	GDSC2	3.2954	4.5707	2.6753	4.1717
LK-2	GDSC1; GDSC2	3.299	5.0395	0.4295	0.4249
HARA [Human squamous cell lung carcinoma]	GDSC1; GDSC2; CTRP2	3.3104	4.7108	3.2931	18.2724
NCI-H1355	GDSC1; GDSC2; CTRP2; CCLE	3.3204	4.2897	3.3185	18.1539
NCI-H1793	GDSC1; GDSC2; CTRP2; CCLE	3.3283	4.3259	3.326	18.1025
NCI-H1963	GDSC1; GDSC2	3.3436	4.8937	0.4984	0.2509
NCI-H1623	GDSC1; GDSC2	3.3447	5.1592	0.4038	0.4708
SBC-3	GDSC1; GDSC2	3.3455	5.0476	0.4445	0.3676
NCI-H522	GDSC2; CTRP2; CCLE	3.3498	4.701	3.3346	18.0028
NCI-H2818	GDSC1; GDSC2	3.364	5.3149	0.3541	0.601
IA-LM	GDSC1; GDSC2; CCLE	3.4212	4.8405	2.4028	2.2638
HCC15	GDSC1; GDSC2; CTRP2; CCLE	3.4248	5.2938	3.3499	17.7071
Lu-134-A	GDSC1; GDSC2	3.4316	5.9659	2.0901	7.2259
NCI-H1693	GDSC1; GDSC2; CTRP2; CCLE	3.4356	5.6449	3.2957	17.8623
NCI-H847	GDSC1; GDSC2	3.4664	4.8897	0.5438	0.1428
Calu-1	CTRP2; CCLE	3.4892	4.6193	3.482	17.0471
NCI-H596	GDSC1; GDSC2	3.4924	5.226	0.4366	0.3293
NCI-H1944	GDSC1; GDSC2; CTRP2; CCLE	3.4973	4.702	3.4869	17.004
HCC1171	CTRP2	3.5172	4.8882	3.4959	16.9081
NCI-H1666	GDSC1; GDSC2; CTRP2; CCLE	3.5175	5.8474	3.3379	17.4583
NCI-H2722	GDSC1; GDSC2	3.524	4.9358	0.5483	0.1256
NCI-H1876	GDSC1; GDSC2	3.5243	4.9235	0.5526	0.1202
ChaGo-K-1	GDSC1; GDSC2; CTRP2	3.5335	6.1883	3.2636	17.677
NCI-H345	GDSC1; GDSC2	3.5641	5.8949	2.2313	6.0163
UMC-11	GDSC1; GDSC2	3.6034	5.4387	0.4027	0.3634
NCI-H250	GDSC2	3.6168	6.1849	2.1281	6.7416
NCI-H513	GDSC1; GDSC2	3.6807	5.6063	0.3722	0.4034
NCI-H322M	GDSC1; GDSC2	3.6832	7.5374	-0.3963	3.4386
HCC4006	CTRP2; CCLE	3.6921	5.0411	3.6661	15.7588
NCI-H2869	GDSC1; GDSC2	3.6927	5.8527	2.3507	4.9736
COR-L23	GDSC1; GDSC2; CCLE	3.7144	5.5962	2.2381	2.5815
Lu-99	CTRP2; CCLE	3.734	5.5378	3.641	15.7106
PaCa-3	GDSC1; GDSC2	3.7928	5.8281	0.3355	0.4451
NCI-H290	GDSC1; GDSC2	3.8187	8.3217	1.223	11.4004
NCI-H1092	GDSC1; GDSC2; CCLE	3.8899	6.8078	1.777	4.5853
NCI-H1975	GDSC1; GDSC2; CCLE	3.9083	6.4173	1.9761	3.5549
NCI-H1836	GDSC1; GDSC2	3.9134	5.6686	2.5974	3.0181
NCI-H1650	GDSC1; GDSC2; CTRP2; CCLE	3.9199	5.6536	3.8196	14.4984
NCI-H2591	GDSC1; GDSC2	4.0024	6.4622	0.1863	0.7436
EMC-BAC-2	GDSC1; GDSC2	4.038	5.8487	0.4185	0.2046
NCI-H2595	GDSC1; GDSC2	4.045	5.8184	0.4313	0.1841
NCI-H1436	GDSC1; GDSC2	4.0457	5.929	2.5609	2.9692
LC-2/ad	GDSC1; GDSC2	4.046	6.227	2.4195	3.784
RERF-LC-A1	CTRP2; CCLE	4.0569	5.4895	3.9978	13.4426
NCI-H647	GDSC1; GDSC2; CTRP2; CCLE	4.0842	5.7463	3.9786	13.4234
SBC-1	GDSC1; GDSC2	4.0918	8.169	1.5063	9.0702
NCI-H2731	GDSC1; GDSC2	4.1513	6.0421	0.3925	0.219
KNS-62	GDSC1; GDSC2; CTRP2	4.1656	5.3898	4.1286	12.6419
NCI-H2135	GDSC1; GDSC2	4.1662	5.8208	2.6863	2.0579
NCI-H3255	GDSC1; GDSC2; CCLE	4.1667	5.9664	2.6198	2.0873
NCI-H1915	GDSC1; GDSC2; CTRP2; CCLE	4.2362	5.905	4.1074	12.4937
Lu-99A	GDSC1; GDSC2	4.2383	6.3348	0.3228	0.3162
NCI-H1563	GDSC1; GDSC2; CTRP2; CCLE	4.2466	5.3905	4.2147	12.0852
LUDLU-1	CTRP2; CCLE	4.2484	6.8515	3.8171	13.5317
NCI-H2444	GDSC1; GDSC2; CTRP2; CCLE	4.2508	5.251	4.1142	6.1883
EMC-BAC-1	GDSC1; GDSC2	4.3204	9.2095	1.1631	10.5114
NCI-H2347	GDSC1; GDSC2	4.3231	6.273	0.3745	0.2081
NCI-H2803	GDSC1; GDSC2	4.3233	8.3641	1.5788	8.1136
NCI-H2170	GDSC1; GDSC2; CTRP2; CCLE	4.4008	5.3197	4.3847	11.0042
Sq-1	CTRP2	4.416	8.6791	3.2077	15.4773
NCI-H1770	GDSC1; GDSC2	4.4167	6.0548	2.7239	1.497
LCLC-97TM1	GDSC1; GDSC2; CTRP2	4.4342	5.9579	4.31	11.1597
IST-SL2	GDSC1; GDSC2	4.4711	8.1097	1.8048	5.4569
SW900	CCLE	4.5887	6.7664	2.2179	1.5613
COR-L32	GDSC2	4.5917	8.1494	1.8668	4.952
COR-L321	GDSC1; GDSC2	4.6212	8.4333	1.7511	6.4881
HOP-62	GDSC1; GDSC2; CTRP2	4.7919	6.7749	4.4265	9.6839
NCI-H446	GDSC1; GDSC2; CTRP2	4.8091	9.566	3.1718	14.6664
NCI-H748	GDSC2	4.9673	7.2791	2.4879	2.0068
NCI-H2228	GDSC1; GDSC2; CTRP2; CCLE	5.0291	8.1729	4.0491	10.5763
NCI-H1105	GDSC1; GDSC2; CTRP2	5.0944	8.8146	3.8053	11.4184
GLC-82	CCLE	5.2267	8.4614	1.8257	2.5169
NCI-H740	GDSC2	5.3558	9.8438	1.5599	6.3871
Hs 229.T	CCLE	5.3733	8.227	1.9993	1.6633
SBC-5	GDSC1; GDSC2; CTRP2; CCLE	5.662	7.576	4.9405	5.4352
NCI-H2227	GDSC1; GDSC2	5.7923	7.7772	2.6669	0.5504
NCI-H510A	GDSC1; GDSC2	5.8072	7.3744	2.8167	0.2088
NCI-H2141	GDSC1; GDSC2; CTRP2	6.1453	10.5279	3.8862	8.8722
NCI-H520	GDSC1; GDSC2; CTRP2; CCLE	6.1684	9.5735	4.3821	6.751
NCI-H1568	GDSC1; GDSC2; CTRP2; CCLE	6.9763	10.9207	3.5175	3.757
A-549	GDSC1; GDSC2; CTRP2; CCLE	7.0959	10.6791	4.534	4.5827
MOR/CPR	CTRP2	7.1563	8.2283	5.6819	0.3168
BEN	GDSC1; GDSC2; CTRP2	7.2319	8.7245	5.5168	0.7265
RERF-LC-Ad1	CTRP2	7.2578	8.1022	5.7699	0.1067
NCI-H526	GDSC1; GDSC2; CTRP2	7.3498	8.8118	5.538	0.5832
HCC95	CTRP2	7.4783	9.2411	5.4238	0.8274
EKVX	GDSC1; GDSC2; CTRP2	7.5228	11.4341	4.4596	4.289
NCI-H226	GDSC1; GDSC2; CTRP2; CCLE	7.5781	8.9906	5.5699	0.3771
HCC1195	CTRP2	7.6313	11.8075	4.3537	4.5617
NCI-H2085	GDSC1; GDSC2; CTRP2; CCLE	7.6422	16.1119	2.2723	12.6824
NCI-H460	GDSC1; GDSC2; CTRP2	7.6522	8.7748	5.6794	0.1433
NCI-H1341	GDSC1; GDSC2; CTRP2; CCLE	7.7163	9.1583	5.5643	0.3295
COR-L95	GDSC1; CTRP2	7.7171	9.2409	5.5333	0.3966
NCI-H2081	GDSC1; GDSC2; CTRP2	7.733	14.8773	2.9439	9.9851
Lu-65	GDSC1; GDSC2; CTRP2	7.7333	10.3087	5.1009	1.6589
VMRC-LCD	GDSC1; GDSC2; CTRP2; CCLE	7.7509	9.8683	5.2977	1.0091
HCC827	GDSC1; GDSC2; CTRP2	7.798	10.034	5.252	1.1135
SHP-77	GDSC1; GDSC2; CTRP2; CCLE	7.8578	9.2244	5.5966	0.2186
COR-L88	GDSC1; GDSC2; CTRP2	7.8585	9.8109	5.3726	0.7225
NCI-H2126	CTRP2	7.8731	9.1329	5.6353	0.1542
NCI-H2122	GDSC1; GDSC2; CTRP2; CCLE	7.8885	9.1294	5.6422	0.141
DMS 114	GDSC1; GDSC2; CTRP2; CCLE	7.9179	10.2729	5.212	1.1462
NCI-H2196	GDSC2; CTRP2	7.9296	9.6325	5.4739	0.4347
DMS 273	GDSC1; GDSC2; CTRP2	7.9316	9.4327	5.5496	0.2787
LCLC-103H	GDSC1; GDSC2; CTRP2; CCLE	7.9583	9.1669	5.6547	0.1112
NCI-H23	GDSC1; GDSC2; CTRP2; CCLE	7.9648	10.2194	5.2571	0.9785
COR-L105	GDSC1; GDSC2; CTRP2	8.0275	12.4012	4.3274	4.1649
NCI-H1395	CTRP2	8.0748	10.6328	5.1399	1.2496
NCI-H838	GDSC1; GDSC2; CTRP2	8.0883	9.2633	5.6679	0.0771
NCI-H322	CTRP2; CCLE	8.0888	14.104	3.5647	7.0388
HCC78	GDSC1; GDSC2; CTRP2; CCLE	8.1283	9.5243	5.5922	0.1564
DMS 79	GDSC1; GDSC2; CTRP2	8.1305	10.1094	5.3767	0.5645
LC-1/sq-SF	CTRP2; CCLE	8.1585	9.389	5.6498	0.0846
HCC1438	CTRP2	8.1625	9.6313	5.5671	0.1835
NCI-H1339	CTRP2; CCLE	8.1961	9.5418	5.6108	0.1198
NCI-H2286	CTRP2; CCLE	8.1981	9.6274	5.5817	0.1553
NCI-H196	GDSC1; GDSC2; CTRP2	8.2002	10.5741	5.2245	0.9175
NCI-H2009	GDSC1; GDSC2; CTRP2; CCLE	8.2413	9.9451	5.4844	0.2953
NCI-H2342	GDSC1; GDSC2; CTRP2	8.2509	10.7507	5.1768	1.0183
T3M-10	CTRP2; CCLE	8.2595	10.0911	5.4378	0.3765
CAL-12T	GDSC1; GDSC2; CTRP2	8.2907	9.9166	5.5139	0.2313
Calu-6	GDSC1; GDSC2; CTRP2	8.3044	11.2437	4.999	1.5099
HCC2108	CTRP2	8.3196	10.3017	5.3836	0.4642
SK-LU-1	GDSC1; GDSC2; CTRP2; CCLE	8.3375	10.3025	5.3907	0.4419
PC-14	GDSC1; GDSC2; CTRP2	8.374	10.0647	5.4926	0.2424
SW1271	GDSC1; GDSC2; CTRP2; CCLE	8.3796	12.8757	4.3229	3.7759
NCI-H650	GDSC1; GDSC2; CTRP2; CCLE	8.3961	10.046	5.5077	0.2137
LOU-NH91	GDSC1; GDSC2; CTRP2; CCLE	8.4197	10.0499	5.5152	0.1972
NCI-H2291	GDSC1; GDSC2; CTRP2	8.4228	12.618	4.4643	3.2152
HCC1588	CTRP2	8.4477	17.0445	2.3956	10.9702
NCI-H1435	GDSC1; GDSC2; CTRP2	8.463	9.7544	5.6322	0.0634
LXF 289	GDSC1; GDSC2; CTRP2	8.4767	12.0238	4.7557	2.1529
NCI-H2172	GDSC1; GDSC2; CTRP2; CCLE	8.4836	10.0422	5.5414	0.1493
NCI-H1838	GDSC1; GDSC2; CTRP2	8.4992	11.8789	4.8297	1.8913
NCI-H1734	GDSC1; GDSC2; CTRP2	8.5073	10.3362	5.4461	0.2804
NCI-H2030	GDSC1; GDSC2; CTRP2; CCLE	8.5225	10.1815	5.507	0.1854
COLO 699	CTRP2; CCLE	8.5254	14.1795	3.8117	5.5187
NCI-H1651	GDSC1; GDSC2; CTRP2; CCLE	8.5307	10.7083	5.3179	0.5166
EBC-1	GDSC1; GDSC2; CTRP2; CCLE	8.5327	10.3285	5.4587	0.2533
NCI-H69	GDSC1; GDSC2; CTRP2	8.5438	10.4116	5.433	0.2917
NCI-H1184	CTRP2; CCLE	8.5463	10.1746	5.5182	0.1659
HCC366	GDSC1; GDSC2; CTRP2	8.5734	10.3547	5.4647	0.2335
NCI-H1869	GDSC1; GDSC2; CTRP2; CCLE	8.5778	10.6542	5.3575	0.4172
NCI-H1373	CTRP2; CCLE	8.6262	13.9714	3.97	4.8041
NCI-H2023	GDSC1; GDSC2; CTRP2; CCLE	8.6369	10.2952	5.5092	0.1595
RERF-LC-MS	GDSC1; GDSC2; CTRP2; CCLE	8.6411	10.2592	5.5232	0.1423
NCI-H292	GDSC1; GDSC2; CTRP2	8.6595	10.268	5.5268	0.1351
NCI-H1755	GDSC1; GDSC2; CTRP2	8.6965	10.4432	5.4793	0.1851
EPLC-272H	GDSC1; GDSC2; CTRP2	8.7603	10.4325	5.5062	0.141
NCI-H2405	GDSC1; GDSC2; CTRP2	8.7646	10.7388	5.4001	0.2831
NCI-H441	GDSC1; GDSC2; CTRP2; CCLE	8.7734	10.232	5.5789	0.0719
SW1573	GDSC1; GDSC2; CTRP2	8.8409	17.2299	2.5756	9.7456
NCI-H727	GDSC1; GDSC2; CTRP2; CCLE	8.8539	10.7369	5.4344	0.2112
RERF-LC-Ad2	CTRP2	8.8562	10.3984	5.5515	0.0844
NCI-H1792	GDSC1; GDSC2; CTRP2; CCLE	8.8634	10.3964	5.5547	0.081
NCI-H1299	GDSC1; GDSC2; CTRP2	8.8665	10.5053	5.519	0.1117
HOP-92	GDSC1; GDSC2; CTRP2	9.0838	11.394	5.2868	0.3786
NCI-H2110	GDSC1; GDSC2; CTRP2	9.0868	11.323	5.3137	0.3328
HCC2279	CTRP2	9.1224	11.018	5.4343	0.16
NCI-H661	GDSC1; GDSC2; CTRP2; CCLE	9.1456	11.1569	5.3946	0.2026
NCI-H889	CTRP2	9.3938	23.4082	-0.0292	17.4207
LK2	CTRP2	9.8009	24.5231	-0.2823	17.5265
NCI-H841	GDSC1; GDSC2; CTRP2	10.2559	18.3154	2.9619	6.6036
HCC1833	CTRP2	11.6301	24.7408	0.8401	11.9119
Hs 888.Lu	CTRP2	8.4961	9.9096	5.5914	0.0938
-----------


⏷ Show the Full List of 225 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1; GDSC2	3.2728	5.2177	0.3531	0.6565
-----------

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
H-STS	CTRP2	6.915	7.8195	5.7349	0.3124
P-STS	CTRP2	7.9394	9.3764	5.5733	0.2339
SYO-1	CTRP2	8.284	10.0012	5.4807	0.2884
-----------

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Yamato-SS	CTRP2	7.2883	8.5887	5.599	0.4548
Aska-SS	CTRP2	7.4944	9.2237	5.4389	0.7712
A-204	GDSC1; GDSC2; CTRP2; CCLE	1.1499	4.775	0.9882	33.1359
EW-8	GDSC1; GDSC2	1.4741	3.2445	0.2441	3.5711
G-402	GDSC1; GDSC2; CTRP2	1.833	6.1983	1.4055	29.4999
TE 441.T	GDSC2; CTRP2	2.3753	3.1296	2.3753	24.4441
SW684	GDSC1; GDSC2	2.8638	3.9257	0.6599	0.1015
Hs 633.T	GDSC1; GDSC2	2.9549	4.7686	0.3901	0.7415
VA-ES-BJ	GDSC1; GDSC2	3.151	7.2179	-0.5519	5.0289
MES-SA	GDSC1; GDSC2; CCLE	3.1756	4.8611	2.2114	3.7521
Hs 729.T	CTRP2	3.2318	5.1003	3.1717	18.9415
Rh30	GDSC1; GDSC2; CCLE	3.3051	5.4724	2.008	4.5371
MFH-ino	GDSC1; GDSC2	3.3126	5.4206	0.2929	0.8277
SW872	GDSC1; GDSC2	3.4682	5.1619	0.4502	0.3085
GCT	GDSC1; GDSC2; CTRP2; CCLE	3.5919	5.7396	3.4446	16.8479
STS-0421	GDSC1; GDSC2	4.4173	6.5657	2.4964	2.6743
TE 617.T	CTRP2; CCLE	4.4396	6.2473	4.2337	11.4199
BT-12	CTRP2	7.2985	8.5556	5.6167	0.4036
SW982	GDSC1; GDSC2; CTRP2	7.8175	8.9628	5.6745	0.1138
KYM-1	GDSC1; GDSC2; CTRP2	7.8426	9.4715	5.4985	0.4184
HT-1080	GDSC1; GDSC2; CTRP2	7.9464	9.3912	5.5706	0.2364
RKN	GDSC1; GDSC2; CTRP2; CCLE	7.9593	9.9004	5.3829	0.6378
BT-16	CTRP2	7.9779	9.3237	5.6069	0.1701
SK-LMS-1	GDSC1; GDSC2; CTRP2	8.2334	9.9625	5.4749	0.3151
SK-UT-1	GDSC1; GDSC2; CTRP2	8.3972	9.9181	5.5532	0.1515
RD	GDSC1; GDSC2; CTRP2	8.4075	10.2563	5.4362	0.3282
G-401	GDSC1; GDSC2; CTRP2; CCLE	8.4605	10.5474	5.3494	0.4786
Tm87-16	CTRP2	8.4854	9.8278	5.6153	0.0742
TTC-709	CTRP2	8.6966	10.1603	5.5765	0.0821
Rh18	GDSC1; CTRP2	12.208	24.8442	1.1493	10.3295
Rh41	GDSC1; GDSC2; CTRP2	12.8345	26.5255	0.7569	10.7983
-----------


⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	8.5675	17.0826	2.4602	10.5576
JHOS-4	GDSC1; GDSC2; CCLE	2.3537	3.6964	2.1437	9.0443
OAW42	GDSC1; GDSC2; CTRP2	2.63	2.9933	2.63	22.747
OVCAR-5	GDSC1; GDSC2; CTRP2	2.686	3.4809	2.6859	22.3745
COV318	CCLE	2.9415	3.7978	2.5513	2.5809
OVKATE	GDSC1; GDSC2	3.023	4.3986	0.5538	0.2434
ES-2	GDSC1; GDSC2	3.0901	4.5525	0.5244	0.2829
A2780	GDSC1; GDSC2; CTRP2; CCLE	3.3156	5.4958	3.1962	18.5896
COV504	CCLE	3.4175	5.5628	2.0477	4.2098
OVMANA	CCLE	3.5874	5.6747	2.1149	3.5167
OC 314	GDSC1; GDSC2; CTRP2; CCLE	3.6743	4.6643	3.6696	15.8054
COV362	CTRP2	3.6914	5.6483	3.5727	16.0845
TYK-nu	GDSC1; GDSC2; CTRP2; CCLE	3.7005	5.8383	3.5396	16.1735
TOV-21G	GDSC1; GDSC2; CCLE	3.8457	8.1867	1.0732	8.2616
Caov-4	GDSC1; GDSC2	3.8696	5.8152	0.3691	0.3412
SNU-119	CTRP2	4.0369	5.5564	3.9649	13.6202
TOV-112D	GDSC1; GDSC2; CTRP2; CCLE	4.1532	7.5746	3.4275	15.2939
EFO-27	GDSC1; GDSC2; CTRP2; CCLE	4.2241	5.6599	4.148	12.3879
OC 316	CCLE	4.3708	6.2993	2.3041	1.4353
OVCAR-3	GDSC1; GDSC2; CCLE	4.6248	6.3984	2.3883	0.8461
SNU-840	CTRP2	5.2905	8.3985	4.1923	9.3734
OC 315	CCLE	5.4057	7.1606	2.427	0.3294
OV56	GDSC1; GDSC2; CTRP2	7.3481	8.2278	5.7592	0.1009
SNU-8	CTRP2	7.5498	8.7823	5.6368	0.2469
FU-OV-1	GDSC1; GDSC2; CTRP2; CCLE	7.9386	9.4011	5.564	0.2503
OVSAHO	CTRP2; CCLE	7.9586	9.29	5.6116	0.1679
DOV13	GDSC1; GDSC2; CTRP2; CCLE	8.0258	9.7727	5.4611	0.4211
COV644	CTRP2	8.1197	9.7792	5.4971	0.3124
SK-OV-3	GDSC1; GDSC2; CTRP2; CCLE	8.139	9.7094	5.5302	0.2475
OVISE	GDSC1; GDSC2; CTRP2	8.1421	9.2234	5.6998	0.0459
ES2	CTRP2	8.1897	9.248	5.7077	0.0371
Caov-3	GDSC2; CTRP2	8.2743	9.7162	5.5786	0.1438
OVK18	GDSC1; GDSC2; CTRP2	8.3512	9.7991	5.5778	0.1305
RMG-I	GDSC1; GDSC2; CTRP2	8.3588	10.3884	5.3672	0.4829
JHOS-2	GDSC1; GDSC2; CTRP2; CCLE	8.3898	9.8409	5.5772	0.1244
JHOC-5	CTRP2	8.39	11.5535	4.9118	1.7175
ONCO-DG-1	CTRP2; CCLE	8.3957	9.6014	5.6603	0.05
OVTOKO	GDSC1; GDSC2; CTRP2; CCLE	8.4678	10.1685	5.4912	0.2205
EFO-21	GDSC1; GDSC2; CTRP2; CCLE	8.4884	9.8357	5.6137	0.0752
COV434	CTRP2	8.5073	12.1706	4.7086	2.2833
OV-90	GDSC1; GDSC2; CTRP2; CCLE	8.5086	10.2398	5.4812	0.2251
JHOM-1	CTRP2	8.5507	9.9513	5.5964	0.0824
IGROV-1	GDSC1; GDSC2; CTRP2; CCLE	8.5885	10.4539	5.435	0.2757
OVCAR-4	GDSC1; GDSC2; CTRP2; CCLE	8.6975	10.2623	5.5422	0.113
Kuramochi	GDSC1; GDSC2; CTRP2; CCLE	8.7161	10.5715	5.4414	0.2329
MCAS	CTRP2; CCLE	8.7354	10.4609	5.4874	0.1673
OVCAR-8	GDSC1; GDSC2; CTRP2; CCLE	8.909	10.5279	5.5262	0.0996
OAW28	GDSC1; GDSC2; CTRP2	9.2372	11.053	5.463	0.1144
OV7	CTRP2	9.5013	21.8869	0.7863	14.8614
HEY A8	CTRP2; CCLE	10.479	18.4889	3.014	6.1852
-----------


⏷ Show the Full List of 50 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IST-Mes2	CCLE	2.8335	4.7065	2.0044	5.8239
MPP 89	GDSC1; GDSC2; CTRP2; CCLE	3.5312	5.1736	3.4811	16.913
NCI-H2452	GDSC1; GDSC2; CTRP2; CCLE	4.2673	8.0825	3.327	15.3849
NCI-H28	GDSC1; GDSC2; CTRP2; CCLE	6.7879	12.3698	3.4779	9.4012
IST-Mes1	GDSC1; GDSC2; CTRP2; CCLE	7.3584	10.1222	4.9687	2.5261
MSTO-211H	GDSC1; GDSC2; CTRP2; CCLE	7.5573	15.4955	2.5127	11.9208
ACC-MESO-1	CTRP2	7.8385	10.0141	5.2803	0.998
NCI-H2052	GDSC1; GDSC2; CTRP2; CCLE	8.8658	10.3108	5.5841	0.0596
JL-1	CTRP2	17.9242	51.9815	-7.9376	22.6297
-----------


⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PC-3	GDSC1; GDSC2; CCLE	3.9558	6.2304	2.0949	2.8939
NCI-H660	GDSC2	4.532	6.5335	2.5772	2.1482
PaCa-3	CTRP2	4.9791	5.6852	4.9566	7.1735
DU145	GDSC1; GDSC2; CTRP2; CCLE	5.5683	8.5153	4.3928	7.9192
VCaP	GDSC1; GDSC2; CTRP2	8.1208	9.6592	5.5412	0.2344
LNCaP clone FGC	GDSC1; GDSC2; CTRP2	8.381	18.7856	1.5006	14.2355
22Rv1	GDSC1; GDSC2; CTRP2; CCLE	8.7314	13.2245	4.3691	3.2405
-----------


⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC1; GDSC2; CCLE	4.0561	6.1332	2.2015	2.2363
YD-15	CTRP2	7.8021	9.0766	5.6285	0.1823
-----------

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1; GDSC2	3.0485	5.4784	2.0081	8.8314
-----------

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HSC-39	GDSC1; GDSC2	1.9502	4.9179	-0.2348	5.4447
SNU-16	GDSC1; GDSC2; CTRP2; CCLE	2.1781	3.4885	2.1763	25.7638
HGC-27	GDSC1; GDSC2; CTRP2; CCLE	2.3995	3.929	2.3922	24.3071
RF-48	GDSC1; GDSC2	2.4213	5.4241	-0.1697	4.1475
GCIY	GDSC1; GDSC2; CCLE	2.5372	3.453	2.3262	4.8602
TGBC11TKB	GDSC1; GDSC2	2.7155	4.8828	0.2333	1.6018
SK-GT-2	GDSC1; GDSC2	2.9513	5.389	0.1393	1.7691
AZ-521	CCLE	3.1853	6.0573	1.6229	7.0121
OCUM-1	GDSC1; GDSC2; CCLE	3.4044	5.3982	2.119	3.7533
ECC10	GDSC1; GDSC2; CTRP2	3.8499	6.7291	3.4329	16.1186
MKN1	GDSC1; GDSC2; CTRP2	3.8667	5.3128	3.8203	14.6655
Hs 746.T	GDSC1; GDSC2; CTRP2; CCLE	4.0986	6.3869	3.8183	13.9594
MKN28	GDSC1; GDSC2	4.2323	6.3245	0.3241	0.3154
KATO III	GDSC1; GDSC2; CTRP2	4.3987	9.568	2.7754	17.2325
BGC-823	CCLE	4.8561	7.5982	2.0013	2.1837
SCH	GDSC1; GDSC2	5.0067	6.2634	2.9106	0.2839
RERF-GC-1B	GDSC1; GDSC2; CCLE	5.535	7.8779	2.2126	0.7907
KE-39	CTRP2; CCLE	5.6425	9.0108	4.2143	8.5044
TMK-1	GDSC1; GDSC2	6.1132	7.8236	2.7717	0.2062
GSU	CTRP2	6.2257	10.9905	3.7208	9.4096
IM95	GDSC1; GDSC2; CTRP2; CCLE	7.311	9.2605	5.3289	1.271
MKN45	GDSC1; GDSC2; CTRP2; CCLE	7.3508	8.5219	5.6525	0.2935
SNU-5	GDSC1; GDSC2; CTRP2	7.5488	8.9333	5.5794	0.3689
NCI-N87	GDSC1; GDSC2; CTRP2; CCLE	7.6603	11.6346	4.4539	4.1331
SNU-620	CTRP2	7.7426	9.1306	5.5854	0.2769
23132/87	GDSC1; GDSC2; CTRP2	7.8622	10.0092	5.2939	0.9415
AGS	GDSC1; GDSC2; CTRP2	8.0146	9.7628	5.4601	0.4279
Fu97	GDSC1; GDSC2; CTRP2	8.0206	9.8415	5.4326	0.4866
GSS	CTRP2	8.0376	9.6242	5.5214	0.2952
MKN7	GDSC1; GDSC2; CTRP2; CCLE	8.0737	11.8172	4.6225	3.0113
NUGC-4	GDSC1; GDSC2; CTRP2; CCLE	8.1087	9.8051	5.4831	0.3432
ECC12	GDSC2; CTRP2	8.1371	9.329	5.6627	0.0755
HuG1-N	CTRP2	8.1468	10.159	5.3647	0.5852
SNU-668	CTRP2	8.1693	9.394	5.6519	0.0812
SNU-719	CTRP2	8.4614	10.332	5.4297	0.3224
SNU-216	CTRP2	8.6844	10.4447	5.4744	0.1942
MKN74	CTRP2; CCLE	8.9464	10.6201	5.508	0.1112
SNU-601	CTRP2	8.97	10.303	5.6214	0.0324
NUGC-3	GDSC1; GDSC2; CTRP2; CCLE	9.0842	19.3929	1.7022	12.4919
SNU-1	GDSC1; GDSC2; CTRP2; CCLE	9.1656	16.747	3.0168	7.6923
LMSU	CTRP2	10.5316	17.5922	3.4421	4.6846
SH-10-TC	CTRP2; CCLE	11.1224	23.317	1.1843	11.4774
SNU-685	CTRP2	7.9654	9.3931	5.5773	0.2195
SNG-M	GDSC1; GDSC2; CTRP2; CCLE	8.1102	14.835	3.2289	8.3147
SNU-1077	CTRP2	8.9687	10.3312	5.6118	0.0368
-----------


⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ASH-3	GDSC1; GDSC2	1.9376	3.5816	0.3815	1.8866
HTC-C3	GDSC1; GDSC2	2.2182	5.0982	-0.1447	4.3743
K5	GDSC1; GDSC2	2.4808	4.1409	0.4249	0.9992
SW579	CTRP2; CCLE	2.4861	8.4337	1.3222	27.736
WRO	GDSC1; GDSC2	2.9478	4.4999	0.4883	0.4361
IHH-4	GDSC1; GDSC2	3.037	4.4248	0.5498	0.2471
8505C	GDSC1; GDSC2; CTRP2; CCLE	3.1025	5.1285	3.0296	19.8468
KMH-2	GDSC1; GDSC2	3.2813	6.4689	1.7144	9.9288
TT2609-C02	GDSC1; GDSC2; CTRP2; CCLE	3.9197	5.6678	3.8166	14.5097
ML-1 [Human leukemia]	GDSC1; GDSC2; CTRP2	4.8602	7.3655	4.2499	10.1908
CAL-62	GDSC1; GDSC2; CTRP2	6.552	9.4837	4.7273	4.6302
CGTH-W-1	GDSC1; GDSC2; CTRP2	7.4515	18.1108	1.14	16.9762
FTC-133	GDSC1; GDSC2; CTRP2	7.9971	11.9841	4.5011	3.5451
TT	GDSC1; GDSC2; CTRP2	8.3026	10.5804	5.2687	0.7408
FTC-238	CTRP2	8.3054	9.4275	5.6874	0.0404
B-CPAP	GDSC1; GDSC2; CTRP2; CCLE	8.3738	16.3676	2.6715	10.057
BHT-101	GDSC1; GDSC2; CTRP2	8.4488	9.9846	5.5488	0.147
8305C	GDSC1; GDSC2; CTRP2; CCLE	8.4606	9.8226	5.6085	0.0829
-----------


⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HO-1-u-1	GDSC1; GDSC2	1.7182	4.514	-0.2004	5.7463
JHU-022	GDSC1; GDSC2	1.8023	3.9121	0.146	3.4707
SAS	GDSC1; GDSC2	1.8835	3.6222	0.3316	2.249
BB30-HNC	GDSC1; GDSC2	2.4559	3.3795	2.3605	8.8786
SCC-4	GDSC1; GDSC2; CTRP2	2.6607	3.6713	2.6601	22.5447
PCI-30	GDSC1; GDSC2	2.703	5.771	-0.1602	3.6226
BICR 10	GDSC1; GDSC2	2.8673	4.8757	0.309	1.1182
OSC-20	GDSC1; GDSC2	2.8794	4.9876	0.2696	1.2703
LB771-HNC	GDSC1; GDSC2	2.9057	6.558	-0.3973	4.5894
NCI-H3118	GDSC1; GDSC2	2.9186	5.4714	0.0883	2.0451
KON	GDSC1; GDSC2	2.9228	4.7467	2.2546	7.7381
BICR 78	GDSC1; GDSC2	2.9763	5.8375	-0.038	2.5888
PCI-04B	GDSC1; GDSC2	3.0065	4.8145	2.2988	7.1996
HO-1-N-1	GDSC1; GDSC2	3.1004	4.6657	0.4878	0.3653
PCI-15A	GDSC1; GDSC2	3.2425	4.8194	2.506	5.2146
SKN-3	GDSC1; GDSC2	3.2963	5.1415	0.3911	0.5302
BB49-HNC	GDSC1; GDSC2	3.3412	5.7372	0.1822	1.2092
SAT [Human HNSCC]	GDSC1; GDSC2	3.3431	13.2698	-3.3087	18.2961
PCI-38	GDSC1	3.3757	6.7755	-0.2308	3.7491
HSC-4	GDSC1; GDSC2; CTRP2	3.4355	5.5676	3.3119	17.8056
PCI-06A	GDSC1; GDSC2	3.4627	5.6787	2.2587	6.1139
KOSC-2	GDSC1; GDSC2	3.4655	6.4856	1.8581	8.546
OSC-19	GDSC1; GDSC2	3.4795	11.1489	-0.4611	21.0458
PE/CA-PJ41 (clone D2)	CTRP2	3.5322	4.955	3.5059	16.8251
Hs 840.T	CCLE	3.5779	6.8257	1.5448	6.5554
Ca9-22	GDSC1; GDSC2	3.5985	5.9168	0.2246	0.8656
YD-8	CTRP2	3.7087	4.4327	3.7082	15.5624
UPCI-SCC-090	GDSC1; GDSC2	3.7251	5.7715	0.3298	0.4881
SCC-15	GDSC1; GDSC2	3.8801	5.6968	0.4143	0.2509
DOK	GDSC1; GDSC2	3.8924	5.7812	0.3894	0.2932
PE/CA-PJ15	GDSC1; GDSC2; CTRP2	4.317	5.8378	4.2113	11.8735
JHU-011	GDSC1; GDSC2	4.607	12.3507	-0.1714	16.7615
HSC-2	GDSC1; GDSC2; CTRP2; CCLE	4.6475	6.3812	4.4162	10.133
PE/CA-PJ49	CTRP2	4.6581	5.3299	4.6516	9.2575
JHU-029	GDSC1; GDSC2	5.0194	8.4894	1.9784	4.4856
FaDu	GDSC1; GDSC2; CTRP2; CCLE	5.0401	7.4068	4.4146	9.0726
PE/CA-PJ34 (clone C12)	CTRP2	7.1927	10.57	4.6522	3.9708
SNU-1066	CTRP2	7.4373	10.6797	4.7592	3.2312
BICR 18	CTRP2	7.7743	9.4385	5.4818	0.4895
SNU-899	CTRP2	7.7996	9.2725	5.5557	0.3144
CAL-27	GDSC1; GDSC2; CTRP2	7.8589	8.9106	5.7072	0.0712
BICR 22	GDSC1; GDSC2; CTRP2	7.9216	9.2855	5.5992	0.1963
YD-10B	CTRP2	8.0092	9.4261	5.5823	0.1994
BICR 56	CTRP2	8.1399	9.4749	5.6137	0.1266
SCC-9	GDSC1; GDSC2; CTRP2	8.1409	10.21	5.3422	0.6429
SCC-25	GDSC1; GDSC2; CTRP2	8.1763	10.0007	5.4376	0.4089
HSC-3	GDSC1; GDSC2; CTRP2	8.2599	15.7033	2.9134	9.31
BHY	GDSC1; GDSC2; CTRP2	8.2733	10.2757	5.374	0.5046
SNU-1076	CTRP2	8.3456	9.6432	5.6291	0.0791
SNU-1214	CTRP2	8.3516	9.94	5.5286	0.194
SNU-46	CTRP2	8.3534	10.0016	5.5073	0.225
CAL-33	GDSC1; GDSC2; CTRP2	8.439	9.9409	5.5604	0.1351
BICR 31	GDSC2; CTRP2	8.4792	10.036	5.5419	0.1495
Detroit 562	GDSC1; GDSC2; CTRP2; CCLE	8.5317	11.5099	5.0008	1.337
SNU-1041	CTRP2	8.6394	10.1029	5.576	0.0893
BICR 16	CTRP2	8.6898	10.1702	5.5708	0.0876
BICR 6	CTRP2	13.2986	32.8886	-1.9203	17.0941
-----------


⏷ Show the Full List of 57 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-BLC1	CTRP2	2.6739	3.3829	2.6738	22.4551
TCCSUP	GDSC1; GDSC2; CTRP2; CCLE	3.1821	4.0641	3.1815	19.071
SW780	GDSC1; GDSC2; CCLE	3.8901	5.8217	2.2439	2.2771
CAL-29	GDSC1; GDSC2; CTRP2	4.0343	5.2999	4.0002	13.5069
BC-3C	CTRP2	4.1203	6.0201	3.9511	13.4098
HT-1197	GDSC1; GDSC2; CTRP2; CCLE	4.3756	5.7057	4.3033	11.3657
UM-UC-3	GDSC1; GDSC2; CTRP2; CCLE	5.2925	7.7314	4.5144	8.0465
BFTC-905	GDSC1; GDSC2; CTRP2	5.407	6.3016	5.2648	4.7611
253J-BV	CTRP2	7.2374	10.1535	4.8786	3.0192
639V	GDSC1; GDSC2; CTRP2; CCLE	7.4773	8.5695	5.6861	0.1804
253J	CTRP2	7.8005	9.2537	5.5631	0.2993
KU-19-19	GDSC1; GDSC2; CTRP2	7.8286	8.9054	5.6983	0.0846
JMSU-1	CTRP2; CCLE	7.9199	9.4147	5.5516	0.279
647V	GDSC1; GDSC2; CTRP2	7.9762	9.385	5.5844	0.2049
RT-112	GDSC1; GDSC2; CTRP2; CCLE	8.1934	9.6626	5.5676	0.1756
RT-4	GDSC1; GDSC2; CTRP2; CCLE	8.2555	10.1481	5.4149	0.4244
SCaBER	CTRP2; CCLE	8.289	9.5984	5.6245	0.0908
UM-UC-1	CTRP2	8.3354	9.9611	5.515	0.2179
SW1710	GDSC1; GDSC2; CTRP2	8.3652	9.9132	5.5431	0.171
VM-CUB-1	CTRP2	8.6493	10.4462	5.4608	0.2209
HT-1376	GDSC1; GDSC2; CTRP2; CCLE	8.7631	16.1312	3.047	8.1036
T24	GDSC1; GDSC2; CTRP2; CCLE	8.8054	15.4852	3.3787	6.8034
KMBC-2	CTRP2; CCLE	8.8082	10.6791	5.4378	0.2167
5637	GDSC1; GDSC2; CTRP2; CCLE	8.9506	10.8026	5.4468	0.1759
J82	GDSC1; GDSC2; CTRP2	9.0209	10.8202	5.4661	0.1421
-----------


⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEY	GDSC1; GDSC2	1.4035	3.7247	-0.0425	5.5155
SKN	GDSC1; GDSC2	1.5946	6.2098	-1.1274	11.6992
MS751	GDSC1; GDSC2	1.9246	3.8457	0.254	2.6156
DSH1	GDSC1; GDSC2	2.2657	5.4717	-0.2895	5.1278
HEC-1	GDSC1; GDSC2	2.4869	6.4799	-0.622	6.6321
SiHa	GDSC1; GDSC2	2.5027	3.7193	0.5982	0.3565
SW756	GDSC1; GDSC2	2.66	4.2153	0.4762	0.6502
TC-YIK	GDSC1; GDSC2	2.6724	4.7952	0.2483	1.5809
NEC8	GDSC1; GDSC2	2.8818	4.2149	0.566	0.2678
OV17R	GDSC1; GDSC2	2.8855	4.7211	2.2321	7.9968
PA-1	GDSC1; GDSC2	2.9328	5.0876	0.2542	1.2837
C-4-I	GDSC1; GDSC2	3.0127	4.7192	0.4331	0.5629
ME-180	GDSC1; GDSC2	3.1077	5.2773	0.2588	1.1078
OVCA433	GDSC1; GDSC2	3.1302	4.3129	2.6588	4.6261
LB831-BLC	GDSC1; GDSC2	3.1639	4.795	0.4656	0.3932
Ca Ski	GDSC1; GDSC2	3.2421	5.5863	0.1972	1.235
PWR-1E	GDSC1; GDSC2	3.2837	5.16	0.3791	0.5714
CAL-39	GDSC1; GDSC2	3.3287	5.2424	0.3667	0.5832
NCC-IT	GDSC2	3.3641	5.1577	0.412	0.4404
JAR	GDSC1; GDSC2	3.3723	4.7886	2.6301	4.0895
DoTc2 4510	GDSC1; GDSC2	3.4925	5.2956	0.4117	0.3858
SKG-IIIa	GDSC1; GDSC2	3.5013	5.0027	0.5176	0.1741
OVCA420	GDSC1; GDSC2	3.518	5.0628	0.503	0.1937
JEG-3	GDSC1; GDSC2	3.5384	5.2645	2.5247	4.2985
C-33 A	GDSC1; GDSC2	3.6321	5.5292	0.3813	0.4015
UWB1.289	GDSC1; GDSC2	3.7428	6.2415	2.1963	5.7847
NT2-D1	GDSC1; GDSC2	3.7912	5.4669	0.4616	0.1944
PEO1	GDSC1; GDSC2	3.8477	5.9921	0.2975	0.5156
KGN	GDSC1; GDSC2	3.869	5.9328	0.327	0.4343
ACC-OV7	GDSC1; GDSC2	3.9279	11.3911	-0.2194	18.7118
JHOS-3	GDSC1; GDSC2	4.1145	5.8678	2.6333	2.4355
OMC-1 [Human cervical carcinoma]	GDSC1; GDSC2	4.1271	6.5248	2.3316	4.1309
OVMIU	GDSC1; GDSC2	4.3502	6.4018	0.34	0.2556
HT-3	GDSC1; GDSC2	4.3737	6.165	0.4284	0.1295
BPH-1	GDSC1; GDSC2	4.5062	7.5696	-0.0217	1.0873
SiSo	GDSC1; GDSC2	4.6081	6.2639	0.4745	0.0627
SW962	GDSC1; GDSC2	5.451	7.1948	2.7452	0.5085
SW954	GDSC1; GDSC2	5.6477	7.4629	2.7249	0.4656
HeLa	GDSC1; GDSC2; CTRP2	11.4881	30.2109	-1.858	19.1361
-----------


⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nilotinib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Nilotinib caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[18]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Nilotinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[19]
-----------

Coadministration of a Drug Treating the Disease Different from Nilotinib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Nilotinib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[20]
Sarecycline	DMLZNIQ	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Sarecycline .	Acne vulgaris [ED80]	[18]
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Nilotinib caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[18]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Ivosidenib.	Acute myeloid leukaemia [2A60]	[21]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Midostaurin.	Acute myeloid leukaemia [2A60]	[21]
Arn-509	DMT81LZ	Major	Increased metabolism of Nilotinib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[18]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[21]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Nilotinib and Levalbuterol.	Asthma [CA23]	[22]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Retigabine.	Behcet disease [4A62]	[21]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Nilotinib caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[23]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[24]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Nilotinib caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[25]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Eribulin.	Breast cancer [2C60-2C6Y]	[21]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[26]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Nilotinib caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Tucatinib	DMBESUA	Major	Decreased metabolism of Nilotinib caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Nilotinib caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Alpelisib	DMEXMYK	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Alpelisib.	Breast cancer [2C60-2C6Y]	[18]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Nilotinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Bosutinib	DMTI8YE	Moderate	Decreased metabolism of Nilotinib caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Nilotinib caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[29]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Nilotinib and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[21]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilotinib and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilotinib and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[22]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Nilotinib due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[20]
Intedanib	DMSTA36	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Intedanib.	Colorectal cancer [2B91]	[31]
Ulipristal	DMBNI20	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Ulipristal.	Contraceptive management [QA21]	[18]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Pasireotide.	Cushing syndrome [5A70]	[21]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Osilodrostat.	Cushing syndrome [5A70]	[21]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Nilotinib caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[32]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Nilotinib caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[18]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Nilotinib caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[18]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Nilotinib caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[33]
Desvenlafaxine	DMHD4PE	Moderate	Decreased metabolism of Nilotinib caused by Desvenlafaxine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[18]
OPC-34712	DMHG57U	Major	Decreased metabolism of Nilotinib caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[34]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Nilotinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[35]
SODIUM CITRATE	DMHPD2Y	Moderate	Decreased absorption of Nilotinib due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[20]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Nilotinib caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[36]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Deutetrabenazine.	Dystonic disorder [8A02]	[21]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Ingrezza.	Dystonic disorder [8A02]	[21]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Nilotinib caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Nilotinib caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Nilotinib caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Nilotinib and Cannabidiol.	Epileptic encephalopathy [8A62]	[19]
Bay 80-6946	DMLOS5R	Moderate	Decreased metabolism of Nilotinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[37]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Nilotinib caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[18]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Nilotinib caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[38]
Dexlansoprazole	DM1DBV5	Moderate	Increased risk of hypomagnesemia by the combination of Nilotinib and Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[18]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Nilotinib caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[20]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Nilotinib caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[19]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Nilotinib caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[18]
Telaprevir	DMMRV29	Major	Decreased metabolism of Nilotinib caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Daclatasvir	DMSFK9V	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Daclatasvir.	Hepatitis virus infection [1E50-1E51]	[18]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[39]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Nilotinib and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[40]
MK-1439	DM215WE	Minor	Decreased metabolism of Nilotinib caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Nilotinib caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Nilotinib caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[42]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Nilotinib caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Raltegravir	DMYURI6	Minor	Decreased metabolism of Nilotinib caused by Raltegravir mediated inhibition of UGT.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Nilotinib and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[45]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Nilotinib and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[46]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Nilotinib and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[47]
Sodium zirconium cyclosilicate	DMCSLZ4	Moderate	Decreased absorption of Nilotinib due to altered gastric pH caused by Sodium zirconium cyclosilicate.	Hyperkalaemia [5C76]	[19]
Aliskiren	DM1BV7W	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[21]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Nilotinib caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[18]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[48]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Nilotinib caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[18]
Suvorexant	DM0E6S3	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Suvorexant.	Insomnia [7A00-7A0Z]	[18]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Nilotinib caused by ITI-007 mediated inhibition of UGT.	Insomnia [7A00-7A0Z]	[49]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Nilotinib and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[50]
Naloxegol	DML0B41	Minor	Decreased metabolism of Nilotinib caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[51]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Nilotinib caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[19]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Nilotinib and Denosumab.	Low bone mass disorder [FB83]	[52]
Brigatinib	DM7W94S	Moderate	Decreased metabolism of Nilotinib caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Nilotinib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[18]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Osimertinib.	Lung cancer [2C25]	[21]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Nilotinib caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[18]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Lumefantrine.	Malaria [1F40-1F45]	[20]
Artesunate	DMR27C8	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Artesunate.	Malaria [1F40-1F45]	[18]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[21]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Nilotinib and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[53]
Idelalisib	DM602WT	Major	Decreased metabolism of Nilotinib caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Nilotinib caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Nilotinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[54]
Ibrutinib	DMHZCPO	Moderate	Decreased metabolism of Nilotinib caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[55]
Ponatinib	DMYGJQO	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Ponatinib.	Mature B-cell lymphoma [2A85]	[18]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Vemurafenib.	Melanoma [2C30]	[21]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Nilotinib and LGX818.	Melanoma [2C30]	[21]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Nilotinib caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[18]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[56]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Nilotinib caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[57]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Nilotinib and Tecfidera.	Multiple sclerosis [8A40]	[58]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Nilotinib and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Nilotinib and Fingolimod.	Multiple sclerosis [8A40]	[59]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Nilotinib and Ocrelizumab.	Multiple sclerosis [8A40]	[60]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Ozanimod.	Multiple sclerosis [8A40]	[21]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Romidepsin.	Mycosis fungoides [2B01]	[21]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[20]
S-297995	DM26IH8	Moderate	Decreased metabolism of Nilotinib caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[19]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Rucaparib.	Ovarian cancer [2C73]	[21]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Triclabendazole.	Parasitic worm infestation [1F90]	[21]
Istradefylline	DM20VSK	Moderate	Decreased metabolism of Nilotinib caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[18]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Pimavanserin.	Parkinsonism [8A00]	[21]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Nilotinib caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[61]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[62]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Lefamulin.	Pneumonia [CA40]	[63]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Nilotinib caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Degarelix.	Prostate cancer [2C82]	[21]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Nilotinib and ABIRATERONE.	Prostate cancer [2C82]	[21]
Enzalutamide	DMGL19D	Major	Increased metabolism of Nilotinib caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[18]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Relugolix.	Prostate cancer [2C82]	[64]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Nilotinib caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[65]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Nilotinib caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[66]
Selexipag	DMAHSU0	Moderate	Decreased metabolism of Nilotinib caused by Selexipag mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[67]
Ambrisentan	DMD1QXW	Moderate	Decreased metabolism of Nilotinib caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[18]
Riociguat	DMXBLMP	Moderate	Decreased metabolism of Nilotinib caused by Riociguat mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[20]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Nilotinib caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[19]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Nilotinib caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[18]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Nilotinib and Canakinumab.	Rheumatoid arthritis [FA20]	[68]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Nilotinib and Rilonacept.	Rheumatoid arthritis [FA20]	[68]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Nilotinib and Golimumab.	Rheumatoid arthritis [FA20]	[69]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Iloperidone.	Schizophrenia [6A20]	[21]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Amisulpride.	Schizophrenia [6A20]	[21]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Asenapine.	Schizophrenia [6A20]	[21]
LDE225	DMM9F25	Moderate	Decreased metabolism of Nilotinib caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[70]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Nilotinib caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[19]
Larotrectinib	DM26CQR	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[20]
PDX-101	DM6OC53	Moderate	Decreased metabolism of Nilotinib caused by PDX-101 mediated inhibition of UGT.	Solid tumour/cancer [2A00-2F9Z]	[71]
Trabectedin	DMG3Y89	Moderate	Decreased metabolism of Nilotinib caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Armodafinil	DMGB035	Minor	Decreased metabolism of Nilotinib caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Nilotinib and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[21]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[21]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Pitolisant.	Somnolence [MG42]	[21]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[21]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Nilotinib caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[72]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[18]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Nilotinib caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[19]
Brilinta	DMBR01X	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Brilinta.	Thrombosis [DB61-GB90]	[18]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Lenvatinib.	Thyroid cancer [2D10]	[21]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Nilotinib and Cabozantinib.	Thyroid cancer [2D10]	[21]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Nilotinib caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[18]
Betrixaban	DM2C4RF	Moderate	Decreased clearance of Nilotinib due to the transporter inhibition by Betrixaban.	Venous thromboembolism [BD72]	[18]
-----------


⏷ Show the Full List of 145 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferric oxide black	E00522	16211978	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Colcothar yellow	E00436	518696	Colorant
Haematite red	E00236	14833	Colorant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
--------------------


⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Nilotinib Hydrochloride Monohydrate eq 50mg base capsule	eq 50mg base	Capsule	Oral
Nilotinib Hydrochloride Monohydrate eq 150mg base capsule	eq 150mg base	Capsule	Oral
Nilotinib Hydrochloride Monohydrate eq 200mg base capsule	eq 200mg base	Capsule	Oral
Nilotinib 150 mg capsule	150 mg	Oral Capsule	Oral
Nilotinib 200 mg capsule	200 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5697).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
6	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
7	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
8	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
9	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87.
10	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
11	Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
12	Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
13	Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation. Toxicol In Vitro. 2016 Mar;31:1-11. doi: 10.1016/j.tiv.2015.11.002. Epub 2015 Nov 6.
14	Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. Chem Biol Interact. 2017 Aug 1;273:171-179. doi: 10.1016/j.cbi.2017.06.012. Epub 2017 Jun 13.
15	AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
16	Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. Chem Biol Interact. 2014 Aug 5;219:203-10. doi: 10.1016/j.cbi.2014.06.009. Epub 2014 Jun 19.
17	p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib. Diseases. 2018 Jan 25;6(1):13. doi: 10.3390/diseases6010013.
18	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
19	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20	Cerner Multum, Inc. "Australian Product Information.".
21	Canadian Pharmacists Association.
22	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
23	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
24	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
25	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
26	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
28	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
29	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
30	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
31	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
32	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
33	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
34	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
35	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
36	Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
37	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
38	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
39	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
40	Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
41	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
42	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
43	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
44	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
45	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
46	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
47	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
48	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
49	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
50	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
51	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
52	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
53	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
54	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
55	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
56	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
57	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
58	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
59	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
60	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
61	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
62	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
63	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
64	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
65	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
66	Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
67	Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
68	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
69	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
70	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
71	Product Information. Beleodaq (belinostat). Spectrum Pharmaceuticals Inc, Irvine, CA.
72	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.